

Summary of Qualifications (CV)

Frederick T. Murphy, DO

Licence/ID #

State/Country:

OS-010717-L

PA/US

Current Work Experience:

YEAR: 2000 to Present

Altoona Center for Clinical Research
175 Meadowbrook Lane
Duncansville, PA 16635
E-Mail: ftmurphy8@gmail.com

CLINICAL TRIALS –INVESTIGATOR OR SUBINVESTIGATOR IN CLINICAL TRIALS CONSISTING OF LOW BACK PAIN, OSTEOARTHRITIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, DIABETIC NEUROPATHY, CHRONIC PAIN, FIBROMYALGIA, INSOMNIA, OBESITY, DYSLIPIDEMIA, PSORIASIS, PSORIATIC ARTHRITIS, GERD, POLYMYALGIA RHEUMATICA, ANXIETY/PANIC DISORDER, LUPUS, METABOLIC SYNDROME, AND RESTLESS LEGS SYNDROME.

YEAR: Feb. 2024 to Present

Clinical Assistant Professor of Rheumatology
Duquesne University of College of Osteopathic Medicine
Two Chatham Center, 4th Floor
112 Washington Place
Pittsburgh, PA 15219

Medical education: 1993 - Doctor of Osteopathic Medicine at Philadelphia College of Osteopathic Medicine in Philadelphia, Pennsylvania. **Currently Board Certified in Rheumatology and Internal Medicine**

Name of school: Villanova University

Name of school: Villanova University

Location PA

Location PA

Dates attended: from 1981 to 1985

Dates attended: from 1985 to 1987

Degree attained: BS Date 1985

Degree attained: BA Date 1987

Postgraduate training (internships, residencies, fellowships):


Name of institution	Address	Dates (from/to)	Type of training
Walter Reed Army Medical Center	Washington, DC	1993/1994	Categorical Internship in Medicine
Walter Reed Army Medical Center	Washington, DC	1994/1996	Residency in Medicine
Walter Reed Army Medical Center	Washington, DC	1996/1998	Fellowship Training
US Army Medical Corps	Washington, DC	1993/2000	Major in US Army

CURRENT UNIVERSITY AFFILIATIONS WITH TITLES AND ADDRESSES:
CLINICAL ASSISTANT PROFESSOR OF MEDICINE, DEPT. OF MEDICINE, UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE, PHILADELPHIA, PA

HOSPITAL AFFILIATIONS WITH TITLES AND ADDRESSES:
CURRENT: ALTOONA UPMC, ALTOONA, PA MEDICAL STAFF, HOSPITAL OF UNIVERSITY OF PA
CURRENT: ENCOMPASS REHAB, ALTOONA, PA MEDICAL STAFF
2000-2014 HOSPITAL OF UNIVERSITY OF PENNSYLVANIA

CURRENT MEDICAL ASSOCIATIONS AFFILIATIONS (UP TO FIVE):
ACP / ACR / AOA / AMA / POMA

SIGNATURE:



DATE

DD-MMM-YYYY

14 MAR 2024

Frederick T. Murphy, DO, FACP, FACR

Memberships in Professional and Scientific Societies and Other Professional Activities:

National:

- 2000-Present American College of Physicians/American Society of Internal Medicine (FACR 2000, 2001) Fellow
- 2000-Present American College of Rheumatology (FACR 2000, 2001)
- 2000-Present American Medical Association (Member 2000, 2001)
- 2000-Present American Osteopathic Association (Member)

Local:

- 2000-Present Pennsylvania Rheumatism Society (Member)

Major Academic and Clinical Teaching Responsibilities:

- 2001-Present Attending Physician, Rheumatology Fellows Clinic, University of Pennsylvania, Philadelphia, PA

Lectures by Invitation:

- San Antonio Feb, 1999 Systemic Sclerosis, Grand Rounds Presentation, Department of
TEXAS Medicine, Brooke Army Medical Center
- San Antonio Sep, 1999 Rheumatological Emergencies, Grand Rounds Presentation,
TEXAS Department of Medicine, Brooke Army Medical Center
- San Antonio Oct, 2001 Systemic Sclerosis, Grand Rounds Presentation, Department of
TEXAS Medicine, Brooke Army Medical Center
- Nemacolin, Jan, 2009 Pennsylvania Osteopathic Medical Association Conference Lecturer
PA in Rheumatology
- Nemacolin Jan, 2011 Pennsylvania Osteopathic Medical Association Conference Lecturer
PA in Rheumatology
- UPENN Mar, 2011 Rheumatology Grand Rounds Lecture, University of Pennsylvania.
PA
- Nemacolin Jan, 2012 Pennsylvania Osteopathic Medical Association Conference Lecturer
PA in Rheumatology
- Altoona Aug, 2012 Greater Altoona Career and Technology Center – Practical Nursing
PA Program
- Pittsburgh
PA

Intellectua

Frederick T. Murphy, DO, FACP, FACR

Bibliography:

Research Publications, peer reviewed (print or other media):

1. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, **Murphy FT**, Magn Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arth spondylitis. *Rheumatology (Oxford)*. 2013 Oct;52(10):1845-55. doi: 10.1093/rheumatology/k PMID: 23838027
2. Brown M, **Murphy FT**, Radin D, Davignon I, Smith M, West C.: Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. *Arthritis and Rheumatism*. 2013 Apr 1. doi:10.1002/art.37950. [Epub ahead of print] PMID: 23553790 [PubMed-as supplied by publisher]
3. Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Kreuger GG, **Murphy FT**, Papp K, Gomez-Reino JJ, Mack M, Beulter A, Gladman D, Kavanaugh A: Markers of inflammation and bone remodeling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. *Ann Rheum Dis*, 2012 Jan;72 (1):83-8. doi: 0.1136/annrheumdis-2012-201697. Epub 2012 Sep 12. PMID:22975755 [PubMed-indexed for MEDLINE]
4. Brown MT, **Murphy FT**, Radin DM, Davignon I, Smith MD, West CR.: Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. *J Pain* 2012 Aug;13(8):790-8. doi: 10.1016/j.jpain.2012.05.006. Epub 2012 Jul 10. PMID:22784777 [PubMed-indexed for MEDLINE]
5. Genovese MC, Han C, Keystone ED, Hsia EC, Buchanan J, Gathany T, **Murphy FT**, Wu Z, Parasuraman S, Rahman MU.: Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. *J Rheumatol*. 2012 June;39(6):1185-91. doi: 10.3899/jrheum.111195. Epub 2012 April 15. PMID:22505702 [PubMed-indexed for MEDLINE]
6. Smolen JS, Kay J, Landewe RB, Matteson EL, Gaylis N, Wollenhaupt J, **Murphy FT**, Zhou Y, Hsia EC, Doyle MK.: Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomized, double-blind, placebo-controlled GO-AFTER study through week 160. *Ann Rheum Dis*. 2012 Oct; 71(10):1671-9. doi: 10.1136/annrheumdis-2011-200956. Epub 2012 March 29. PMID:22459542 [PubMed-indexed for MEDLINE]

Frederick T. Murphy, DO, FACP, FACR

7. Webster LR, Peppin JF, **Murphy FT**, Tobias JK, Vanhove GF.: Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. *J Pain Res.* 2012;5:7-13. doi: 10.2147/JPR.S25272. Epub 2012 Jan 20.
PMID:22328830[PubMed]
8. Webster LR, Peppin JF, **Murphy FT**, Lu B, Tobias JK, Vanhove GF.: Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. *Diabetes Res Clin Pract.* 2011 August;93(2):187-97. doi: 10.1016/j.diabres.2011.04.010. Epub 2011 May 25.
PMID:1612836 [PubMed-indexed for MEDLINE]
9. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N, **Murphy FT**, Neal JS, Zhou Y, Visvanathan S, Hsai EC, Rahman MU; GO-AFTER study investigators: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. *Lancet.* 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 June 26. Erratum in: *Lancet.* 2009 Oct 24;374(9699):1422.
PMID:19560810 [PubMed-indexed for MEDLINE]
10. Smolen J, Zhou Y, Zamani O, Neal J, **Murphy FT**, Wollenhaupt J, Gaylis N, Matteson E, Landewe R, Doyle M, Kay J, Visvanathan S, Hsia E, Rahman M.: Golimumab, A New Human Anti-TNF-Alpha Monoclonal Antibody, Injected Every 4 weeks: Efficacy and Safety in RA Patients Previously Treated with Anti-TNF Alpha Agent(s) (GO-AFTER Study). *Lancet* 374(9685): 210-21, Jul 2009 Notes: Epub 2009 Jun 26. Erratum in: *Lancet.* 2009 Oct 24;374(9699):1422.
11. Genovese MC, Keystone EC, Hsia HC, Buchanan J, Klareskog L, **Murphy FT**, Wu Z, Parasuraman S, Rahman MU.: Golimumab Significantly Improves Physical Function, Health-Related Quality of Life, and Fatigue in Rheumatoid Arthritis Patients: Results from the GOFORWARD study. *Ann Rheum Dis.* 68(6): 789-96, Jun 2009 Notes: Epub 2008 Dec. 9.
PMCID: PMC2674549
12. Terkeltaub R, Sundry JS, Schumacher HR, **Murphy FT**, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A. The interleukin 1 inhibitor rilovcept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. *Ann Rheum Dis* 2009 Oct;68(10):1613-7. doi: 10.1136/ard.2009.108936. Epub 2009, Jul 26.

Frederick T. Murphy, DO, FACP, FACR

13. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, **Murphy FT**, Musser TK, Staniero N, Vincente-Gonzales AV, Grossbard E.: Treatment of rheumatoid arthritis with Sky kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. *Arthritis Rheum.* 2008 Nov;58(11):3309-18. doi: 10.1002/art.23992. PMID:18975322 [PubMed-indexed for MEDLINE]
14. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, **Murphy FT**, Wittmer BA, Aversano ML, Reicin AS; Protocol 071 Study Group: Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. *May Clin Proc.* 2005 Apr;80(4):470-9. PMID:15819283 [PubMed-indexed for MEDLINE]
15. **Murphy FT**, Kivitz AJ, Sands EE.: Management of postmenopausal osteoporosis. *J Am Osteopath Assoc.* 2003 Oct;103(10 Suppl 6):S6-11. PMID:14620079 [PubMed-indexed for MEDLINE]
16. Hepburn MJ, Battafarano DF, Enzenauer RJ, Salzberg DJ, **Murphy FT**, Parisek RA, Kroenke K.: Increasing resident research in a military internal medicine program. *Mil Med.* 2003 Apr;168(4):341-5. PMID:12733683 [PubMed-indexed for MEDLINE]
17. Del Rincòn I, Battafarano DF, Arroyo RA, **Murphy FT**, Fischbach M, Escalante A.: Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles. *Arthritis Rheum.* 2003 Apr 15;49(2):200-8. PMID:12687511 [PubMed-indexed for MEDLINE]
18. Abel MP, **Murphy FT**, Enzenauer RJ, Enzenauer RW.: Internuclear ophthalmoplegia (INO): an unusual presentation of neuropsychiatric lupus erythematosus. *Binocul Vis Strabismus Q.* 2003;18(1):29-30. PMID:12597766 [PubMed-indexed for MEDLINE]
19. Del Rinòn I, Battafarano DF, Arroyo RA, **Murphy FT**, Fischbach M, Escalante A. Heterogeneity between men and women in the influence of the HLA-DRB1 shared epitope on the clinical expression of rheumatoid arthritis. *Arthritis Rheum.* 2002 Jun;46(6):1480-8. PMID:12115177 [PubMed-indexed for MEDLINE]
20. Happe MR, Battafarano DF, Dooley DP, Rennie TA, **Murphy FT**, Casey TJ, Ward JA. Validation of the Disease Mini-Ves erythrocyte sedimentation rate (ESR) analyzer using the Western ESR method in patients with systemic inflammatory conditions. *AM J Clin Pathol.* 2002 Jul;118(1):14-7. PMID:12109848 [PubMed-indexed for MEDLINE]

Frederick T. Murphy, DO, FACP, FACR

21. Zapor M, **Murphy FT**, Enzenauer R. Echolalia as a novel manifestation of neuropsychiatric systemic lupus erythematosus. *South Med J* 2001 Jan;94(1):70-2.
PMID:11213948 [PubMed-indexed for MEDLINE]
22. Zapor M, Rennie T, **Murphy FT**, Battafarano DF. Clinical images: Neuropsychiatric systemic lupus erythematosus. *Arthritis Rheum.* 2000 Sep;43(9):2045. No abstract available.
PMID:11014355 [PubMed-indexed for MEDLINE]
23. Shorr AF, **Murphy FT**, Gilliland WR, Hnatiuk W. Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. *Respir Med.* 2000 Mar;94(3):228-32.
PMID:10783933 [PubMed-indexed for MEDLINE]
24. **Murphy FT**, Enzenauer RJ, Battafarano DF, David-Bajar K. Etanercept-associated injection-site reactions. *Arch Dermatol.* 200 Apr;136(4):556-7. No abstract available.
PMID:10768663 [PubMed-indexed for MEDLINE]
25. **Murphy FT**, George R, Kubota K, Fears M, Pope V, Howard RS, Dennis GJ. The use of Western blotting as the confirmatory test for syphilis in patients with rheumatic disease. *J Rheumatol.* 1999 Nov;26(11):2448-53.
PMID: 10555908 [PubMed-indexed for MEDLINE]
26. **Murphy FT**, Enzenauer RJ. Clinical Images: Geographic tongue. *Arthritis Rheum.* 1999 Mar; 42(5):1061. No abstract available.
PMID:10323465 [PubMed-indexed for MEDLINE]
27. **Murphy FT**, Enzenauer RJ, Cheney CP. *Arthritis Rheum.* 1999 Mar;42(3):573. No abstract available.
PMID:10088782 [PubMed-indexed for MEDLINE]
28. Shorr AF, **Murphy FT**, Kelly WF, Kaplan KJ, Gilliland WR, Shapeero LG. Osseous sarcoidosis clinical, radiographic and therapeutic observations. *J Clin Rheumatol.* 1998 Aug;4(4):186-92. No abstract available.
PMID: 19078289 [PubMed-indexed for MEDLINE]
29. **Murphy FT**, Manown TJ, Knutson SW, Eliasson AH. Epinephrine-induced lactic acidosis in the setting of status asthmaticus. *South Med J.* 1995 May;88(5):577-9.
PMID:12115177 [PubMed-indexed for MEDLINE]
30. Godino J, Butani RJ, Wong PK, **Murphy FT**.: Acute drug-induced pancreatitis associated with celecoxib. *J Clin Rheumatol.* 5(5): 305-307, Oct . 1999.

Frederick T. Murphy, DO, FACP, FACR

31. Smolen, Josef S, Kay, Jonathan, Doyle Mittie, Landewew Robert, Matteson, Eric, Gaylis, N, Wollenhaupt, J, Murphy Frederick, Xu Stephen, Zhou Yiying. : Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors: findings with up to 5 years of treatment in the multicenter, randomized, double-blind, placebo- controlled, phase 3 GO-AFTER study. (IN PRINT)

Contributions to peer-reviewed clinical research publications, participation cited but not by authorship:

- 1 Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies
Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG, Heterogeneity Collaborative Study Group. Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. doi: 10.1002/acr.22212. PMID: 24151254 [PubMed - indexed for MEDLINE]
- 2 The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies
Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW, Child Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013 Jul;92(4):223-43. doi: 10.1097/MD.0b013e31829d08f9. PMID: 23877355 [PubMed - indexed for MEDLINE]
- 4 Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of a double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Leung AM, Doyle MK; PSUMMIT 1 Study Group. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Aug 27. PMID: 23769296

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG, Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013 Jan;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d. PMID: 23263716 [PubMed - indexed for MEDLINE]

Frederick T. Murphy, DO, FACP, FACR

1. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.: Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 30(11): 1988-2004, Nov 2008.
2. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, Tobias J; NGX-4010 C116 Study Group.: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 12: 1106-12, Dec 2008 Notes: Epub 2008 Oct 30. Erratum in: Lancet Neurol. 2009 Jan;8(1):31.
3. Mamurova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.: Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 58(12): 3941-50, Dec 2008. PMID: PMC2674642
4. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthi S, Mack M, Visvanathan S, Beutler A.: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4): 976-86, Apr 2009.
5. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study.: Golimumab, a human antibody to tumour necrosis factor {alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 68(6): 789-96, Jun 2009 Notes: Epub 2008 Dec 9.
6. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.: Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 94(9): 3215-25, Sep 2009 Notes: Epub 2009 Jun 30.

Frederick T. Murphy, DO, FACP, FACR

7. Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial.: Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int. 21 (Suppl 2)(7): 1277-85, Jul 2010 Notes: Epub 2009 Oct 3.
8. Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group.: Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res. 26(5): 984-92, May 2011 Notes: doi: 10.1002/jbmr.292.
9. Shah, M., Mamyrova, G, Targoff, IN, Huber, AM, Malley, JD, Rice, M, Miller, FW, Rider, LG.: The Clinical Subgroup Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
10. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG.: Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 87(2): 70-86, Mar 2008. PMID: PMC2674585

Abstracts: POSTER PRESENTATION only

1. Murphy FT, Dennis GJ.: The Clinical Significance of Reactive Fluorescent Treponemal Antibody serologies in patients with systemic lupus erythematosus. Arthritis Rheum. 38(9): Suppl, 1995.
2. Murphy FT, Pugh AM, Larsen SA, George RA, Dennis GJ.: The Confirmation of false positive syphilis serologies in patients with autoimmune disease. Arthritis Rheum.(39), Suppl, 9 1996.
3. Murphy FT, Shorr AF, Gilliland WR, Shapeero LG.: The varying spectrum of osseous and sarcoidosis: clinical, radiographic pathologic observations. Arthritis Rheum. 40: S1422, 1997.
4. Murphy FT, Dennis GJ, George R, Kuota D, Fears M, Pope V, StC. Morgan W, Faghiri Z and Wilson WA.: Discordance to cardiolipin and beta 2- glycoprotein-1 antibodies in HTLV-1-associated tropical spastic paraparesis. Arthritis Rheum. 41(9): S308, 1998.

Frederick T. Murphy, DO, FACP, FACR

5. **Murphy FT**, Pasquena PF, Prieto R, Dennis GJ.: A phase one clinical trial of intra-articular ketorolac in acute gouty arthritis. Arthritis Rheum. 41(9): S152, 1998.
6. **Murphy FT**, Shorr AF, Gilliland WR, Shapeero LG, Dennis GJ.: Clinical Markers for disease activity in patients with osseous sarcoidosis. Arthritis Rheum. 41(9): S229, 1998.
7. Abel MP, **Murphy FT**, Enzenauer RJ, Enzenauer RW.: Internuclear ophthalmoplegia: an unusual presentation of neuropsychiatric lupus erythematosus (NPLE). South Med J 92: S83, 1999.
8. Garrett PD, **Murphy FT**, Battafarano DF.: Migratory oligoarthritis secondary to group F streptococcus. South Med J. 92: S85, 1999.
9. Zapor MJ, **Murphy FT**, Enzenauer RJ.: Echolalia as a manifestation of neuropsychiatric lupus. South Med J. 92: S83-S84, 1999.
10. Happe MR, Rennie TA, **Murphy FT**, Dooley DP, Battafarano DF, Casey TJ. : Validation of the Diesse Mini-VES Automated System Using the Westergren Erythrocyte Sedimentation Rate in Patients With Systemic Inflammatory Conditions. Arthritis Rheum. 43(a): S498, 2000.
11. **Murphy FT**, Helman DL, Bolton JD, Emmons EE, Argyros GJ.: The Prevalence of the Anti-Jo-1 Antibody in Subjects with Idiopathic Pulmonary Fibrosis. Chest 118(4): 95s, 2000.
12. **Murphy, FT**, Kivitz, AJ, Zumer, MJ, Marvasti, A, Flagg, SD, Kolasinski, SL^{III}. Arthritis Rheum 2003;48;(9)Suppl.:1223:S623: The Clinical Utility of the High-Sensitivity Quantitative Determination of C-Reactive Protein (hs-CRP) by Latex Particle Enhanced Immunoturbidimetric Assay in Patients with Inflammatory Rheumatic Disease. Arthritis Rheum. 48(9, Suppl 1223): S623, 2003.
13. Furst D, Buchanan J, Rahman M, **Murphy FT**, Han J, Keystone E, Kavanaugh A, Deodher A, Moreland L, Kay J, Wasko M, Doyle M.: Golimumab, A New Human Anti-TNF-Alpha Monoclonal Antibody Administered Subcutaneously Every 4 Weeks, Improves Anemia and Well-Being in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. Arthritis Rheum. 58(9): S545, 2008.
14. Kavanaugh A, Mack M, Beutler A, Livingston J, Antoni C, **Murphy FT**, Mease P, Krueger G, Gladman D, Gomez-Reino J, Papp K, Mudiwarthy S, McInnes.: Golimumab Administered Subcutaneously Every 4 Weeks in Psoriatic Arthritis Patients: 52 Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-REVEAL Study. Arthritis Rheum. 58(9): S414, 2008.

Frederick T. Murphy, DO, FACP, FACR

15. Kavanaugh A, Mack M, Beutler A, Livingston J, Antoni C, **Murphy FT**, Mease P, Krueger G, Gladman D, Gomez-Reino J, Papp K, Mudivarthi S, McInnes I. : Golimumab, a New Human, TNF Alpha Antibody Administered Subcutaneously Every 4 Weeks in Psoriatic Arthritis Patient. Ann Rheum Dis 67(12), 2008.
16. Radin A, Mellis S, Bookbinder S, Yang K, **Murphy FT**, Biedermann S, Schumacher HR, Sundry J, Terkeltaub R.: Placebo-Controlled Pilot Study of Rilonacept (IL-TRAP), A Long Acting IL-1 Inhibitor, in Refractory Chronic Active Gouty Arthritis. Ann Rheum Dis. 67(12), 2008.
17. Smolen J, Zhou Y, Zamani O, Neal J, **Murphy FT**, Wollenhaupt J, Gaylis N, Matteson E, Landewe R, Doyle M, Kay J, Visvanathan S, Hsia E, Rahman M.: Golimumab, A New Human Anti-TNF-Alpha Monoclonal Antibody, Subcutaneously Administered Every 4 weeks in Patients with Active Rheumatoid Arthritis Who Were Previously Treated with Anti-TNF Alpha Agent(s). Ann Rheum Dis. 67(12), 2008.
19. LR Webster; John F Peppin, DO, **Frederick T Murphy, DO**; J Tobias; GF Vanhove: Tolerability of NGX-4010 in Conjunction with Three Topical Anesthetic Formulations for the Treatment of Neuropathic Pain. AAPMed Page: C111, 2010.
20. Smolen JS, Kay J, Landewe R, Matteson EL, Gaylis N, Wollenhaupt J, **Murphy FT**, Amani O, Zhou Y, Hsia EC, Doyle MK.: Golimumab Administered Subcutaneously Every Four Weeks in Patients With Active Rheumatoid Arthritis Who Were Previously Treated With Anti-TNFAlpha Agent(s): Efficacy Results of the Randomized, Double-Blind, Placebo-Controlled, Go-After Study through Week 160. Ann Rheum Dis. 70(Supp 3): 710, 2011.


Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

- In Press
2012
1. Frederick T. Murphy: Questions You Will Be Asked on Rounds, In the Clinic, On Oral Exams. Rheumatology Secrets: 3rd Edition. Hanley & Belfus, Philadelphia, Page: Chapters 52 & 53, In Press.- 2012

PubMed

Abstract

Full text links



Arthritis Res Ther. 2015 Jan 22;17(1):14. [Epub ahead of print]

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor γ inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.

Simolen JS, Kay J, Doyle M, Landewé R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC.

Abstract

Introduction The aim of this study was to assess long-term golimumab therapy in rheumatoid arthritis (RA) patients who discontinued previous tumor necrosis factor- γ (TNF)-inhibitor(s). **Methods** Patients enrolled into this multicenter, randomized, double-blind, placebo-controlled study of active RA (≥ 4 tender, ≥ 4 swollen joints) received placebo (Group 1) or golimumab 50 mg (Group 2) or 100 mg (Group 3) injections every 4 weeks. Patients in Groups 1 and 2 with inadequate response at week 16 escaped to golimumab 50 and 100 mg, respectively. At week 24, Group 1 patients crossed-over to golimumab 50 mg, Group 2 continued golimumab 50/100 mg per escape status, and Group 3 maintained dosing. During the long-term-extension (LTE), golimumab 50 mg could be increased to 100 mg, and 100 mg could be decreased to 50 mg. Data through 5 years are reported for all patients (safety) and patients using methotrexate (efficacy, intention-to-treat (ITT) analysis with last-observation-carried-forward for missing data and non-responder imputation for unsatisfactory efficacy discontinuations). **Results** In total, 459 of 461 randomized patients received the study agent, 304 of whom were methotrexate-treated and included in efficacy analyses. Through week 256, the proportions of methotrexate-treated patients achieving American-College-of-Rheumatology (ACR) responses were 37.6% to 47.0% for ACR20, 21.4% to 35.0% for ACR50, and 7.8% to 17.0% for ACR70 response across randomized groups. Golimumab safety through week 268 was generally consistent with that at week 24 and week 160 and other anti-TNF agents. **Conclusions** In some patients with active RA discontinuing previous TNF-antagonist therapy, golimumab safety and efficacy, assessed conservatively with ITT analyses, was confirmed through 5 years. **Trial registration** Clinicaltrials.gov NCT00299546. Registered 03 March 2006.

PMID: 25627338 [PubMed - as supplied by publisher]

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

K. B. Gordon^a, K. Reich^b, J. J. Crowley^c, N. J. Korman^d, F. T. Murphy^{e,f}, Y. Poulin^{g,h}, L. Spelman^{ij}, P. S. Yamauchi^k, A. M. Mendelsohn^l, J. Parno^l, S. J. Rozzo^l and C. N. Ellis^m

^aMedical College of Wisconsin, Milwaukee, WI, USA; ^bCenter for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation[®], Hamburg, Germany; ^cBakersfield Dermatology, Bakersfield, CA, USA; ^dUniversity Hospital Cleveland Medical Center, Cleveland, OH, USA; ^eAltoona Arthritis and Osteoporosis Center, Duncansville, PA, USA; ^fVillanova University, Villanova, PA, USA; ^gCentre Hospitalier de l'Université Laval, Hôpital Hôtel-Dieu de Québec, Québec City, QC, Canada; ^hCentre de Recherche Dermatologique du Québec Métropolitain, Québec City, QC, Canada; ⁱVeracity Clinical Research, Brisbane, QLD, Australia; ^jProbit Medical Research, Waterloo, ON, Canada; ^kDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ^lSun Pharmaceutical Industries, Inc, Princeton, NJ, USA; ^mDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA

ABSTRACT

Background: It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment.

Objectives: To evaluate supplementing dichotomous efficacy with residual disease activity.

Methods: This post hoc analysis used pooled, patient-level data after tildrakizumab 100 mg ($N=616$) or placebo ($N=309$) treatment from reSURFACE 1/2 (NCT01722331/NCT01729754) phase 3 clinical trials of patients with moderate to severe plaque psoriasis.

Results: Median baseline Psoriasis Area and Severity Index (PASI) was 17.9 for patients receiving tildrakizumab 100 mg. At Week 12, median PASI was 2.9, whereas dichotomous PASI 90 response rate was 36.9%, and absolute PASI <5.0 , <3.0 , and <1.0 were 64.0%, 50.8%, and 23.3%, respectively. At Week 28, median PASI was 1.7, whereas PASI 90 response rate was 51.9%, and absolute PASI <5.0 , <3.0 , and <1.0 were 75.3%, 62.8%, and 38.0%, respectively. Dermatology Life Quality Index and PASI scores were correlated through Week 28 ($r=0.51$, $p \leq .0001$).

Conclusions: Disease activity was more reliably estimated by PASI scores than percentage PASI improvement; this may partially explain efficacy disparities between clinical trials and practice. These results suggest supplementing dichotomous PASI improvement with PASI scores and consideration of patient treatment goals could facilitate clinical decisions.

ARTICLE HISTORY

Received 12 February 2020

Accepted 5 March 2020

KEYWORDS

Psoriasis; disease activity; tildrakizumab; Psoriasis Area and Severity Index (PASI)

Frederick T. Murphy, DO, FACP, FACR

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

Calcium Pyrophosphate Deposition Disease (Chapter46); **Murphy, Frederick T.** Rheumatology Secrets: 3rd Edition, pp 346 – 351. 2015:Elsevier- Mosby Publishers, Philadelphia, PA. ISBN978-0-323-03700-6.

Basic Calcium Phosphate and other Crystalline Diseases (Chapter47); **Murphy, Frederick T.** Rheumatology Secrets: 3rd Edition, pp 352 – 356. 2015:Elsevier- Mosby Publishers, Philadelphia, PA. ISBN978-0-323-03700-6.

Intellectual Property, Registered Patents, Trademarks & Copyrights:

1. EON[®] is a lightly carbonated citrus lifestyle beverage launched in New York City and featured on FOX Business News.
2. FORMULA5[®] is a lightly carbonated hydrating beverage developed to provide hydration, anti-oxidants, vitamins, electrolytes and nutrients in every drop.
Containing less than 5 calories per serving, it is gluten free, vegan friendly, GMO free and diabetic friendly. FORMULA5[®] has four delicious flavors including Orange fusion, Atomic Grape, Black Cherry and Lemon lime. It will be launched in 2015.
3. TRIN[™] Sparkling water is a nutritional brand of flavorful clear sparkling water.

RHEUMnotes[®] is a collection of mind-maps creatively developed to instruct and educate medical students, residents and fellows in the art of rheumatological diseases.

Frederick T. Murphy, DO, FACP, FACR



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MARCH 24, 2014

PTAS

THE WEBB LAW FIRM
420 FT. DUQUESNE BLVD.
ONE GATEWAY CENTER, STE. 1200
PITTSBURGH, PA 15222

502732405

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 03/21/2014

REEL/FRAME: 032493/0477
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 7341-140435


ASSIGNOR:
MURPHY, FREDERICK T.

DOC DATE: 03/21/2014

ASSIGNEE:
FORTIS BEVERAGES, LLC
1737 S. LOGAN BLVD.
HOLLIDAYSBURG, PENNSYLVANIA 16648


APPLICATION NUMBER: 61954794
PATENT NUMBER:
TITLE: NUTRITIONAL BEVERAGE PRODUCT

FILING DATE:
ISSUE DATE:




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

SPONSOR	DIAGNOSIS	DRUG	# OF PTS ENROLLED
Sanofi L8890	(Prostate) BPH	Registry and Survey	33
Boehringer Ingelheim	Abdominal Cramping/Pain	Hyoscine Butylbromide	2
Sepracor	Adult Insomnia	Zopiclone	8
Novartis CVAK694A2201	Allergy / Seasonal Rhinitis	VAK694	1
Luitpold 1VIT09030	Anemia	FERRIC CARBOXYMALTOSE	7
GSK 205270	Anemia	Novel Prolyl Hydroxylase Inhibitor Daprodustat	1
Noven	Ankle Sprain Pain	Ketoprofen Patch	15
UCB SCHWARZ AS001	Anklosing Spondylitis	Certolizumab Pegol	9
Roche WA22908	Anklosing Spondylitis	Tocilizumab	4
Roche NA22823	Anklosing Spondylitis	Tocilizumab	6
Pharmacia 193	Ankylosing Spondylitis	Celecoxib	21
Immunex 016.0037	Ankylosing Spondylitis	Etanercept	16
Abbott M03-607	Ankylosing Spondylitis	Adalimumab	16
Centocor C0524T09	Ankylosing Spondylitis	Golimumab	24
SANOFI AVENTIS DRI11073	Ankylosing Spondylitis	SAR153191	5
NOVARTIS CAIN457A2209	ANKYLOSING SPONDYLITIS	AIN457	4
Celgene T-CC-10004-AS001	Ankylosing Spondylitis	Apremilast	8
Novartis CAIN457F2305	Ankylosing Spondylitis	Secukinumab	7
Novartis CAIN457F2310	Ankylosing Spondylitis	Secukinumab	2
Merck 0663-108	Ankylosing Spondylitis	MK-0663	7
Pfizer A3921119	Ankylosing Spondylitis	Tofacitinib	2
JANSSEN CNTO148AKS3001	Ankylosing Spondylitis	GOLIMUMAB	7
NOVARTIS CAIN457F2320	Ankylosing Spondylitis	SECUKINUMAB	4
AbbVie M13-375	Ankylosing Spondylitis	Adalimumab	15
Janssen CNTO1275AKS3001	Ankylosing Spondylitis	Ustekinumab	0
UCB AS0008	Ankylosing Spondylitis	Bimekizumab	3
Lilly I1F-MC-RHBX	Ankylosing Spondylitis	Ixekizumab (LY2439821)	0
Lilly I1F-MC-RHBW	Ankylosing Spondylitis	Ixekizumab	1
Novartis CAIN457H2315	Ankylosing Spondylitis	Secukinumab	6
Novartis CAIN457K2340	Ankylosing Spondylitis	Secukinumab	3
Novartis CAIN457FUS06	Ankylosing Spondylitis	Secukinumab	20
UCB AS0011	Ankylosing Spondylitis	Bimekizumab	2




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Novartis CAIN457P12301	Ankylosing Spondylitis & NR Axial SpondyloArthritis	Secukinumab	5
Schwarz	Anxiety or Panic Disorder	Niravam	5
Targeted Genetics I3G01 (Phase 1)	Arthritis (Inflammatory)	TNFR-Fc Fusion Gene	14
Byk Gulden/Altana	Asthma	Roflumilast	0
Pfizer Esperion 642-006	Atherosclerosis	ETC-642	9
Medimmune D6080C00001 Phase 1	Autoimmune Diseases	MEDI7734	8
Janssen CNT01959NAP0001	Autoinjector	AUTOINJECTOR	31
BMS IM133-060	Autoinjector	AUTOINJECTOR	28
Coherus CHS-1420-04	Autoinjector Device for Rheumatoid Arthritis	CHS-1420	8
Harris Interactive	Avinza Pain Questionnaire	Avinza	8
Merck P07642 (MK8259-006)	Axial Spondylitis	Simponi	5
Abbott M10-791	Axial Spondyloarthritis	Humira	1
Janssen CNT01275AKS3002	Axial Spondyloarthritis	Ustekinumab	0
AbbVie M19-944	Axial Spondyloarthritis	Upadacitinib	5
Abbott F12-117	Axial Spondyloarthritis – Back Pain	Questionnaire	25
UCB AS0005	axSpA Axial Spondyloarthritis	Certolizumab Pegol	1
Biovail	Back Pain	Tramadol	20
Pharmacia 244	Back Pain	Celecoxib	21
Pharmacia 269	Back Pain	Celecoxib	8
Purdue BUP3015	Back Pain	BTDS	13
Endo EN3261-001	Back Pain	Lidocaine Patch	7
Dov Pharm. 020 & 022	Back Pain	Bicifadine	11
Hisamitsu HKT400US04	Back Pain	Ketaprofen Patch	0
Pfizer A3191165	Back Pain	Celecoxib	3
Abbott M05-790	Back Pain	Vicodin	3 (Closed Early)
Purdue BUP3024	Back Pain	BTDS	11
Neuromed NMT 1077-301	Back Pain	NMED-1077	2
Johnson and Johnson 42160443PAI2003	Back Pain	JNJ 42160443	7
Pfizer A4091012	Back Pain	Tanezumab	18
Purdue ONU3701	Back Pain	Oxycodone/Naloxone	14
Pfizer B4531002	Back Pain	ALO-02	6
Endo EN3409-308	Back Pain	Buprenorphine	1
Endo EN3409-307	Back Pain	Buprenorphine	Open Label=10 Double-Blind=4
TEVA C33237/3103	Back Pain	CEP-33237	5




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

PFIZER B7431006	Back Pain	PF-06372865	4
Lilly	Biomarkers in RA	None	24
Merck 141	Biomarkers of Inflammation in RA/OA	No Drug	94
Pharmacia 201	Bursitis –Tendinitis Shoulder	Celecoxib	39
Merck 065	Cardiac Biomarkers in Pts with OA	Etoricoxib vs. Celecoxib, Ibuprofen	22
Bayer 12198	Cardiovascular Events	Aspirin	1
CIRT (National Heart Lung & Blood Institute)	Cardiovascular Events	MTX	14
AstraZeneca 4522US/001.1	Cardiovascular Events in Low to Normal Level of LDL-C & CRP	Crestor®	0
Endo EN3272-301	Carpal Tunnel Syndrome	Lidocaine Patch	3
Orthobiotech	Chronic Kidney Disease	Epoetin Alfa	5
Amgen 20110226	Chronic Kidney Disease	Darbepoetin	0
Nektar 14-181-07	Chronic LBP	NKTR-181	1 Completed 21 Screened
Regeneron R475-PN-1524	Chronic LBP	Fasinumab	3
Pfizer A4091059	Chronic LBP	Tanezumab	10
Nektar 14-181-08	Chronic LBP or Noncancer Pain	NKTR-181	2
Egalet OC-EG-302	Chronic Low Back Pain	EGALET-002	2
Egalet OC-EG-303	Chronic Non Cancer Pain	Egalet-002 ADER Oxycodone	8
Endo	Chronic Pain	Numorphan	6
Purdue Pharma	Chronic Pain	Hydromorphone Hydrochloride ER	17
Biovail	Chronic Pain	Tramadol	67
Endo Pharmaceuticals	Chronic Pain	Oxymorphone	26
Shire 308	Chronic Pain	Propiram Fumarate	10
Endo EN3202.028	Chronic Pain	Oxymorphone	5
Abbott M03-666	Chronic Pain	Vicodin	12
Sagedmed	Chronic Pain	Questionnaire	17
Johnson & Johnson R331333-PAI-3007	Chronic Pain	CG5503 PR	28
Cephalon C25608/3054/BP/US	Chronic Pain	Fentanyl Buccal	10
Cephalon C25608/3055/BP/MN	Chronic Pain	Fentanyl Buccal	4
Sanofi-Synthlebo	Chronic Painful Shoulder	Hyalgan	16
Regeneron 0505	CIASI	IL-1 Trap	3
AstraZeneca D7000C00001 SuperNova	COVID-19 Pre-Exposure Prophylaxis	AZD5156/AZD3152	3
Abbott M02-403	Crohn's Disease	Adalimumab	1
Abbott M02-404	Crohn's Disease	Adalimumab	1




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Abbott M06-808	Crohn's Disease	Adalimumab	4
Pfizer A3921043	Crohn's Disease	CP-690,550	3
CORRONA	Data Collection on OA, RA, OP, PSA	None	In Progress
IOMED	DeQuervain's Disease	Iontophoresis	12
Centocor CNTO C0999D02	Device Trial for Autoinjector	AUTOINJECTOR	38
Bristol-Myers Squibb	Diabetes	Metformin	1
Novartis 2302	Diabetes & Cardio outcomes in Impaired Glucose Intolerance	Nateglinide & Valsartan	2
Abbott	Diabetic Neuropathy	ABT594	7
Sanwa	Diabetic Neuropathy	SNK-860	2
Pfizer A0081060	Diabetic Neuropathy	Pregabalin	5
Astellas 05-0-223	Diabetic Neuropathy	FK1706	3
Takeda 01-06-TL-583-006	Diabetic Neuropathy	TAK-583	6
Johnson & Johnson R331333-PAI-3015	Diabetic Neuropathy	CG5503	11
Adolor 33CL231	Diabetic Neuropathy	ADL5859	4
Sangamo SB-509-0601	Diabetic Neuropathy	SB-509	0
Forest RG8-MD-02	Diabetic Neuropathy	RGH-896	6
AEGERA AEG33773-201	Diabetic Neuropathy	AEG33773	15
JOHNSON & JOHNSON R331333-PAI-3027	Diabetic Neuropathy	TAPENTADOL	11
Pfizer A0081268	Diabetic Neuropathy	PREGABALIN	3
Daiichi Sankyo DS5565-AU201	Diabetic Neuropathy	DS-5565	2
Pfizer A0081269	Diabetic Neuropathy	PREGABALIN	2
AstraZeneca D3031C00001	Diabetic Neuropathy	AZD5213	1
Aptinyx NYX-2925-2008	Diabetic Neuropathy	NYX-2925	2
Sangamo SB-509-0107	Diabetic Neuropathy (Mod/Severe)	SB-509	2
Pfizer 1008-160	Disturbed Sleep from Neuropathic Pain	Pregabalin	2
Alcon	Dry Eye in CTD Patients	Rimexolone	8
Abbott M10-275	Dyslipidemia	ABT-335	2
ABBOTT M10-313	DYSLIPIDEMIA	ABT-335	4
Centocor	Early Rheumatoid Arthritis	Remicade	20
IOMED	Epicondylitis	Iontophoresis	2
Hisamitsu HKT400US05	Epicondylitis	Ketaprofen Patch	1
AstraZeneca D9612100062	Erosive Esophagitis	Nexium®	1
TAP Z-EE05-123	Erosive Esophagitis	Ilaprazole	13
AstraZeneca D9612L00084	Esophageal Mucosal Pathology	Prilosec OTC	1
Lilly/Boehringer Ingelheim	Female Stress Urinary Incontinence	Duloxetine HCl	10
Pfizer A2571003	Fibromyalgia	CP-424,391	22




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Pfizer A0081056	Fibromyalgia	Pregabalin	7
Cypress Bioscience	Fibromyalgia	Milnacipran	13
Orphan	Fibromyalgia	Xyrem	13
Forest MLN-MD-02	Fibromyalgia	Milnacipran	8
Pfizer A6061034	Fibromyalgia	Reboxetine	7
Wyeth 3151A4-327-US	Fibromyalgia	DVS SR	19
Allergan 203818-503	Fibromyalgia	AGN 203818	6
Pfizer A6061043	Fibromyalgia	Reboxetine	11
Pfizer A6061046	Fibromyalgia	Reboxetine	8
Boehringer Ingelheim 248.637	Fibromyalgia	Pramipexole	8
Wyeth 3151A4-2003-US	Fibromyalgia	DVS SR	7
Lilly F1J-MC-B020	Fibromyalgia	Questionnaire	150
Pfizer FMS BOI	Fibromyalgia	Questionnaire	25
Jazz 06-009 and 06-010	Fibromyalgia	Xyrem	14
Jazz FMS Interview	Fibromyalgia	Interview/Questionnaire	5
Jazz 06-010	Fibromyalgia	Xyrem	14
Bioenergy Ribocor BIOE02C010	Fibromyalgia	D-Ribose	27
OMC Research SLS2009001	Fibromyalgia	Pregabalin	130
Theravance TD9855 Protocol 0092	Fibromyalgia	TD-9855	10
DAIICHI DS5565-A-E311	Fibromyalgia	DS-5565	5
Teva TV48125-PN-20028	Fibromyalgia	Fremanezumab	3
Aptinyx NYX-2925-2005	Fibromyalgia	NYX-2925	8
Lilly F1J-MC-HMGW	Fibromyalgia adolescents	Duloxetine	5
Cypress Bioscience	Fibromyalgia Questionnaire	None	193
Pfizer A0081165	Fibromyalgia with Insomnia	Pregabalin	1
Parke-Davis/Pfizer	Fibromyalgia, Post Herpetic Neuralgia, Diabetic Neuropathy	Pregabalin	3
Horizon HZ-CA-303	For Patients Requiring NSAIDs	HZT-501	97
Logical LT-NS001-003	Gastric Ulcers	LT-NS001	25
Pozen PA32540-302	Gastric Ulcers	PA32540	9
Genomics	Genotype	DNA	2,316
Reliant	GERD	Nizatidine ER	4
Altana BY1023/M3-340	GERD	Pantoprazole	25
AstraZeneca D9120C00027	GERD	AZD3355	2
Eisai E3810-G000-302	GERD	Rabeprazole	1
Eisai E3810-G000-303	GERD	Rabeprazole	9
Tap T-GD04-082	GERD (non-erosive)	TAK-390MR	19




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

AstraZeneca D9770C00012	GERD Esophagitis	AZD0865	3
AstraZeneca D9770C00011	GERD w/o Erosive Esophagitis	AZD0865	3
Sepracor	Geriatric Insomnia	Zopiclone	5
Adolor Corp.	GI Dysfunction (Opioid-Induced)	Opioid Therapy	6
AstraZeneca 0003	GI Symptoms (relief)	Esomeprazole	8
AstraZeneca 0004	GI Symptoms (rollover)	Esomeprazole	4
Adolor	GI Symptoms from Opioids	Data Collection Study	1
Centocor	Giant Cell Arteritis	Infliximab	4
Merck	Glucocorticoid-Induced Bone Loss	Alendronate	9
Merck	Gout	Etoricoxib & Indomethacin	3
Bio-Technology General	Gout	None	4
Tap C02-010	Gout	TMX-67	2
Tap	Gout	Febuxostat	1
Savient C0406	Gout	Peg-Uricase	4
Regeneron IL1T-A1-0608	Gout	Rilonacept	4
Tap F-GT06-153	Gout	Febuxostat	9
AR Scientific MPC-004-06-001	Gout	Colchicine	13
Regeneron IL1T-GA-0619	Gout	IL-1 Trap	4
Novartis CACZ885H2255	Gout	Canakinumab (ACZ885)	4
Enzymerx ENZ-101	Gout	Uricase PEG 20	10
Regeneron IL1T-GA-0810	Gout	Rilonacept	2
Enzymerx ENZ-102 PHASE 1	Gout	URICASE-PEG 20	12
Biocryst BCX4208-201	Gout	BCX4208	1
Novartis CACZ885H2357	Gout	ACZ885	2
Biocryst BCX4208-202	Gout	BCX4208	3
Regeneron IL1T-GA-0815	Gout	Rilonacept	10
NUON A3007GT	GOUT	TRANILAST	4
Biocryst BCX4208-203	Gout	BCX4208	5
Takeda TMX_67-204	Gout	Febuxostat	1
Metabolix M102-21122	Gout	MBX 102	1
ARDEA ALLO-401	GOUT	ALLOPURINOL	7
NOVARTIS CACZ885H2361	Gout	ACZ885	1
REGENERON IL1T-GA-1103	Gout	Colchicine (Colcrys®)	0
Ardea RDEA594-304	Gout	Lesinurad	1
Ardea RDEA594-301	Gout	Lesinurad	3




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Takeda FEB-XR_301	Gout	Febuxostat	7
Takeda FEB-XR_201	Gout	Febuxostat	1
Ardea RDEA3170-207	Gout	Febuxostat	
Takeda TMX-67_301	Gout	Febuxostat	31
Selecta SEL-212/101 PHASE 1	Gout	SEL-212	3
Selecta SEL-212/201	Gout	SEL-212	1
Recipe – Dr. Saag	Gout	KRYSTEXXA	7
SELECTA SEL-212/202	Gout	Krystexxa	2
Ampel AMP-001	Gout	Pegloticase	15
LG CHEM LG-GDCL002	Gout	LC350189	3
Horizon HZNP-KRY-202	Gout	Krystexxa/Pegloticase	5
ArthroSi AR882-202	Gout	AR882	3
Selecta SEL-212/302	Gout	SEL-212	3
Horizon HZNP-KRY-403	Gout	Pegloticase	10
LG Chem LG-GDCL009	Gout	Tigulixostat	1
Pfizer A3191219	Gouty Arthritis	Celebrex	1
AstraZeneca 325	Healed EE	Nexium	4
Tap T-EE04-084	Healing Erosive Esophagitis	TAK-390MR	24
Pfizer A9451141	Healthy	Gabapentin	108
Pfizer A3191171	Healthy	Celebrex	40
ARRAY ARRAY-797-101 PHASE 1	Healthy	ARRY-371797	36
Regeneron R375-PN-0817 PHASE 1	Healthy	REGN 475	19
Primus PIV-01 with Influenza Shot	Healthy	Botanical Source	44
Primus BCPS-01	Healthy	Botanical Source	27
AggreGuide VAL0085	Healthy	ADP Assay for Antiplatelet Drugs	49
Navidea NAV3-35	Healthy	Tc 99m Tilmanocept	39
PLX Pharma	Healthy – on Aspirin	Aspirin-PC (ASA-PC)	23
Pfizer A3471019	Healthy Elderly	Bextra®	32
Pharmacia 258	Healthy Subjects	Celecoxib	30
Asterand	Healthy, Lupus	Genetic Blood collection	1000+
Seracare	Healthy, Psoriasis, Lupus, RA, MS	Genetic Blood Collection	300+
AstraZeneca	Heartburn & Sleep disturbances	Esomeprazole	6
SELECTA SEL-037	HIGH URIC ACID LEVELS	SEL-037	5




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Pharmacia	Hypercholesterolemia	SD-5613	11
AstraZeneca 4522US/0003	Hypercholesterolemia	Rosuvastatin, Atorvastatin, Simvastatin	2
Abbott M10-667	Hypercholesterolemia	ABT-143	13
Merck MK-0616-008	Hypercholesterolemia	MK-0616	5
Abbott M05-749	Hyperlipidemia	Fenofibric Acid	4
Abbott – KOS Life Sciences 019-05-06-CR	Hyperlipidemia	Niacin ER & Zocor	12
Abbott M10-229	Hyperlipidemia	Niaspan	4
Amgen 20101154	Hyperlipidemia	AMG 145	11
Pfizer B1481005	Hyperlipidemia	PF-04950615	3
Pfizer B1481012	Hyperlipidemia	PF-04950615	0
Sanofi LTS11717	Hyperlipidemia	REGN727/SAR23655 3	1
Pfizer B1481015	Hyperlipidemia	PF-04950615	11
Amgen 20110109	Hyperlipidemia	AMG 145	9
Amgen 20110114	Hyperlipidemia	AMG 145	8
Amgen 20110115	Hyperlipidemia	AMG145	9
Amgen 20120348	Hyperlipidemia	AMG145	5
Amgen 20120356	Hyperlipidemia	AMG 145	4
Pfizer B1481020	Hyperlipidemia	PF-04950615	4
Regeneron R727-CL-1532	Hyperlipidemia	Praluent	1
Bristol Myers Squibb	Hypertension	Omapatrilat or Enalapril	4
Pharmacia 145	Hypertension	Celecoxib vs Rofecoxib	11
Alteon	Hypertension	ALT-711	3
NicOx HCT3012-X-104	Hypertension with ABP	HCT 3012	Sponsor Cancelled
Searle	Hypertension with OA	Celecoxib vs Rofecoxib	34
GlaxoSmithKline	IBS in Females	Alosetron	2
Neurocrine Biosciences	Insomnia	NBI-34060	6
GlaxoSmithKline MAD103894	Insomnia	GW679769	0
Sepracor 190-904	Insomnia	Eszopiclone	4
Merck 009-00	Insomnia	MK-0822	6
Forest	Irritable Bowel Syndrome	Dexloiglumide	3
Bristol Myers 033	JRA	BMS-188667	3
Horizon HZ-CA-402-01	JUVENILE IDIOPATHIC ARTHRITIS	DUEXIS®	2
Boehringer Ingelheim	Juvenile Rheumatoid Arthritis	Meloxicam	17
Regeneron R475-PN-1612	LBP and OA Hip or Knee	Fasinumab	1




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Amgen 20010223	Low Bone Mineral Density	AMG 162	12
Zalicus Z160-LSR-201	Lumbar Radiculopathy	Z160	3
Eliem ETX-018810-201	Lumbosacral Radicular Pain	ETX-018810	2
LaJolla – LJP	Lupus	LJP - 394	3
Genelabs	Lupus	Prestara™	2
LaJolla LJP394-90-14	Lupus	LJP394	2
LaJolla LJP394-90-16	Lupus	ABETIMUS SODIUM	Sponsor Closed Study
Genentech U2971g	Lupus	Rituximab	0
MEDIMMUNE MI-CP126	Lupus	MEDI-545	1
Schering Plough P03722 PHASE 1	Lupus	IL-10	13
Human Genome Sciences	Lupus	Belimumab	6
Amgen 20060203 PHASE 1	Lupus	AMG 811	6
Genentech IFN3958g	Lupus	rhuMAb IFNalpha	0
Medimmune MI-CP179	Lupus	MEDI-545	1
AMGEN 20070283	Lupus	AMG 811	7
Wyeth 3227K2-1002-NA	Lupus	SIB-087	10
AMGEN 20060132	Lupus	AMG 557	21
Cephalon C33457/2047	Lupus	CEP-33457	1
Argos Novo Nordisk AGS-009-001	Lupus	NNC0152-0000-0001	7
AMGEN 20060169	Lupus	AMG 557	6
CENTOCOR CNTO136LUN2001	Lupus	CNTO 136	0
Lilly H9B-MC-BCDT	Lupus	LY2127399	5
HGS 1006-C1115 BLISS	LUPUS	BELIMUMAB	0
INVION PHASE 1	LUPUS	INV103/Ala-chaperonin 10	4
UCB SL0009	LUPUS	EPRATUZUMAB	3
LILLY H9B-MC-BCEI	LUPUS	LY2127399	5
HGS 1006-C1117	Lupus	Belimumab Vaccine	1
GSK 200339	LUPUS	BELIMUMAB	2
RESOLVE PHASE 1B 132-02	LUPUS	RSLV-132	4
BIOGEN 230LE101	LUPUS	BIIB059	1
CELGENE CC-220-SLE-001	LUPUS	CC-220	1
HGS1006-C1113	LUPUS	BELIMUMAB	11
XENCOR XmAb5871-04	LUPUS	XmAb5871	1
Mallinckrodt	LUPUS	MNK14304067	1
Nektar 17-358-02	LUPUS	NKTR-358	2




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

HGS1006-C1124	LUPUS	BENLYSTA	26
Amgen 20170103	LUPUS	AMG 592	5
Idorsia ID-064A202	LUPUS	Cenerimod	1
Amgen 20170103	LUPUS	AMG592	5
AstraZeneca D3461R00001	LUPUS OBSERVATIONAL	OBSERVATIONAL	5
Janssen NOCOMPOUNDLUP0001	LUPUS Rash	No Drug	1
Abbott M03-598	Metabolic Syndrome	Tarka® & Hyzaar®	2
AstraZeneca 322	Moderate/Severe EE	Nexium	4
Biogen (Phase 1) 101MS101	Multiple Sclerosis	Natalizumab	4
NeurogesX	Neuropathic Pain	NGX 4010	4
Tap aka Takeda T-GD07-170	Nocturnal GERD	TAK-390MR	4
TAP T-GD05-137	Non-Erosive GERD	TAK-390 MR	17
Purdue HMP4005	Non-Malignant Pain	Hydromorphone® HCl ER and Duragesic	42
Merck 205	Normal Subjects	Alendronate Sodium	17
UCB AS0010	NR Axial Spondyloarthritis	Bimekizumab	4
Novartis CAIN457P12301	NR Axial Spondyloarthritis or AS	Secukinumab	6
Horizon HZ-CA-401	NSAID	HZT-501	36
AstraZeneca 286	NSAID associated Gastric Ulcers when Daily NSAID is continued	NEXIUM	2
AstraZeneca 288	NSAID associated Gastric Ulcers when daily NSAID is D/C	NEXIUM	3
Pozen PN400-302	NSAID Induced Ulcers	PN400	36
Pozen PN400-304	NSAID Induced Ulcers	PN400	24
Pozen PN400-303	NSAID Induced Ulcers	PN400	1
Pozen PN400-301	NSAID Induced Ulcers	PN400	2
Tap LAN-0003-0041	OA	Celebrex - Naproxen	97
Wyeth 3189A1-104-US PHASE 1	OA	AGG-523	10
Merck 057-00	OA	Ibuprofen	17
Neuromed NMT 1077-302	OA	NMED-1077	9
Pfizer GI Reasons A3191331	OA	Celebrex	23
Regeneron R475-PN-0901	OA	REGN 475	19
Pfizer A4091026	OA	Tanezumab	13
Samumed	OA	SM04690	4
GLAXOSMITHKLINE RHO2448	OA	PARACETAMOL	3
Genzyme SYVN-004-02	OA Hip	Synvisc®	9
Pfizer 1045-0008	OA Hip or Knee	CI-1045	14
Sanofi L-9385	OA Knee	Hyalgan	13




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

GlaxoSmithKline CXA30007	OA Knee	GW406381	7
McNeil 17-007	OA Knee	IDEA-033/23 (Ketoprofen in Transfersome®)	13
Endo EN3260-001	OA Knee	Lidocaine 5%	16
Pfizer A3191173	OA Knee	Celecoxib	12
NicOx	OA Knee	HCT3012	29
Forest 02	OA Knee or Hip	ML3000	23
Johnson and Johnson R331333-PAI-2020	OA (End Stage Joint Disease)	Tapentadol IR & Oxycodone IR	8
XOMA X052160	OA HAND	GEVOKIZUMAB	6
XOMA X052162	OA HAND	GEVOKIZUMAB	4
AbbVie M14-171	OA Hand	ABT-981	6
GSK 204851	OA Hands	GSK3196165	1
Novartis COX189A2367	OA Hip	Lumiracoxib	13
Nicox HCT3012-X-303	OA Hip	Naproxcinod	5
Pfizer A4091014	OA Hip	Tanezumab	9
GENZYME SYNVO4910/EFC12791	OA HIP	SYNVISC	9
Biovail B02.CT3.023.TRA P02	OA Hip and/or Knee	Tramadol HCl ER	40
Pharmacia 010	OA Hip or Knee	Celecoxib	17
Grunenthal KF5503/09	OA Hip or Knee	CG5503 or Oxycodone	16
McNeil 98-055	OA Hip or Knee	Acetaminophen and Naproxen	4
Purdue OXY4003	OA Hip or Knee	OxyContin®	16
Purdue BUP3012	OA Hip or Knee	BTDS	19
McNeil 00-104	OA Hip or Knee	Acetaminophen ER	7
Alpharma ALO-KNT-301	OA Hip or Knee	Kadian NT	9
Alpharma ALO-KNT-202	OA Hip or Knee	Kadian NT	13
Iroko MEL3-12-02	OA Hip or Knee	Meloxicam	1
CARA CR845-CLIN2001-PO	OA HIP OR KNEE	CR845	24
Regeneron R475-PN-1227	OA HIP OR KNEE	FASINUMAB	7
Cara Therapeutics	OA Hip or Knee	CR845	15
Pfizer A4091058	OA Hip or Knee	Tanezumab	3
Primus POAC-01	OA Hip or Knee	PC-010	30
United Therapeutics	OA Knee	Ketotop	21
Biovail	OA Knee	Tramadol	32
Pharmacia/Pfizer	OA Knee	Compare Celecoxib to Rofecoxib	18
Merck 150	OA Knee	Rofecoxib	28




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Dimethaid	OA Knee	PENNSAID	17
Forest Laboratories	OA Knee	ML3000	35
Novartis 0109	OA Knee	COX189	35
Searle 158	OA Knee	Celecoxib	58
Pharmacia	OA Knee	Valdecoxib/Celecoxib	21
AstraZeneca 0010	OA Knee	AR-P900758XX	45
Pharmacia 142	OA Knee	Valdecoxib	35
Merckle ML3-MD-01	OA Knee	ML3000	15
Alticor	OA Knee	Magna Bloc™	9
Pharmacia 008	OA Knee	SD-6010	27
Labopharm	OA Knee	Tramadol HCl	17
Pfizer A4141004	OA Knee	CI-1027	29
Novartis 2360	OA Knee	Lumiracoxib	12
Pfizer A3191082	OA Knee	Celebrex	6
Pfizer A6171009	OA Knee	SD-6010	20
Amgen 20040100	OA Knee	Anakinra	9
Pfizer A3191152	OA Knee	Celebrex & Naproxen	16
J & J R3313333-PA1-2001	OA Knee	CG5503	8
Endo EN3220-012	OA Knee	Lidocaine Patch	20
Wyeth TD-04-02	OA Knee	TDS-943	13
Pfizer A5231011	OA Knee	CJ-023,423	18
Novartis VOSG-PN-304	OA Knee	Diclofenac Gel	2
Pfizer A5231001	OA Knee	CJ-023,423	27
Regeneron 0425	OA Knee	IL-1 Trap	18
Primus	OA Knee	Limbrel	39
Seikagaku SI-6606/01 PHASE 1	OA Knee	Synvisc or GEL-200	18 Double Blind 7 Open Label
BIONICARE	OA Knee	Knee Device	10+
Astellas 04-0-211	OA Knee	FK555	35
FLEXX FPI-EUFLX-2005-01D PHASE 1	OA Knee	EUFLEXXA	11
Wyeth 3175A1-202-WW	OA Knee	PLA-695	20
Pfizer A6341008	OA Knee	CE-224,535	16
Rinat RN624-CL006	OA Knee	RN624	4
Amgen 20060145 PHASE 1	OA Knee	AMG 403	4
NicOx HCT3012-X-302	OA Knee	Naproxinod	11
Zars ZMK-301	OA Knee	ThermoProfen	24
Endo EN3260-003	OA Knee	Lidocaine	11




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Johnson and Johnson R331333-PAI-3008	OA Knee	CG5503	6
Wyeth TD-07-14A	OA Knee	TDS-943	21
Pfizer A6171016	OA Knee	SD-6010	12
Combinatorx CRx-102-006	OA Knee	CRx-102	3
Hisamitsu HKT-500-US12	OA Knee	HKT-500	24
Pozen PN400-307	OA Knee	PN 400	8
IDEA CL-033-III-06	OA Knee	Ketoprofen	10
Merck 105-00	OA Knee	Naproxen and Ultracet	16
Anika 0702	OA Knee	Monovisc	19
Purdue BUP3025	OA Knee	BTDS	9
Pfizer A4091011	OA Knee	Tanezumab	18
Pfizer A4091015	OA Knee	Tanezumab	16
Adolor 44CL240	OA Knee	ADL5859 & ADL5747	22
Pfizer A4091027	OA Knee	Tanezumab	5
Bayer 15256	OA Knee	UC-11	7
LILLY F1J-US-HMGL	OA KNEE	Duloxetine	8
STRYKER 09-OA-002	OA KNEE	BMP-7	19
LILLY TREADMILL H7L-MC-TRED	OA Knee	NAPROSYN	24
NOVARTIS CACZ885C2201	OA Knee	CANAKINUMAB	46
ABBOTT M10-889	OA KNEE	ABT 652	18
J & J 42160443PAI2006	OA KNEE	JNJ-42160443	2
Iroko DIC3-08-05	OA KNEE	Diclofenac Nanoformulation	25
ABBOTT M13-237	OA KNEE	ABT 652	11
ARRAY 797-223	OA KNEE	ARRY-371797	5
IROKO D1C3-08-06	OA KNEE	DICLOFENAC	21
NOVUM DCL-269	OA KNEE	DICLOFENAC SODIUM	2
FLEXION FX-006-2011-001	OA KNEE	FX006 TO KENALOG	2
Fidia R29-09-02	OA KNEE	Hymovis	14
Purdue VND2001	OA Knee	V116517	22
Nektar 12-181-04	OA Knee	NKTR-181	13
Ampio AMP-003-A	OA Knee	Ampion	15
Q-MED Dusk 35GA1203	OA Knee	Durolane	4
Afferent AF219-004-OA	OA Knee	AF 219	7
Forest GRT-MD-101	OA KNEE	GRT6005	13
Flexion FX006-2013-005	OA Knee	FX006	26




Altoona Center for Clinical Research
 175 Meadowbrook Lane, Duncansville PA 16635

TECHFIELDS TF-X0002-21	OA KNEE	X0002	5
Ampio AP-004-A	OA Knee	Ampion	15
SEIKAGAKU GEL/1133	OA KNEE	GEL ONE	8
Flexion FX006-2014-006	OA Knee	FX006	13
AbbVie M13-741	OA KNEE	ABT-981	2
Flexion FX006-2014-008	OA KNEE	FX006	8
CYTORI ACT-OA	OA KNEE	Adipose Derived Regenerative Cells	6
SAMUMED SM04690-OA-02	OA KNEE	SM04690	5
CENTREXION 4975-OA-502	OA KNEE	CNTX-4975	2
FLEXION FX006-2015-009	OA KNEE	FX006	13
Vertex VX15-150-101	OA Knee	VX-150	17
Samumed SM04690-OA-04	OA Knee	SMO4690	5
3V Medical	OA Knee	3vM1001 Cream	50
Flexion FX006-2017-012	OA Knee	FX006	10
Seikagaku Corp. 613/1121	OA Knee	SI-613	5
Unity UBX0101-OAR-101	OA KNEE	UBX0101	14
Galapagos CL2-201086-002/GLPG1972-CL-201	OA Knee	S201086/GLPG1972	9
Flexion FX006-2017-014	OA Knee	FX006	24
Ampio AP-013	OA Knee	Ampion	74
Unity UBX0101-MUS-201	OA KNEE	UBX0101	11
Calibr CBR-KA34-3001	OA Knee	KA34	12
TAIWAN LIPOSOME TLC 599A3005	OA KNEE	TLC599	3
SAMUMED SM04690-OA-11	OA KNEE	SM04690	1
SAMUMED SM04690-OA-10	OA KNEE	SM04690	1
Novartis CLNA043X2202	OA KNEE	LNA043	0
Paradigm PARA_OA_002	OA Knee	Pentosan Polysulfate Sodium	1
Grunenthal KF7039-02	OA Knee	RTX-GRT7039	4
SAMUMED SM04690-OA-15	OA KNEE –	RADIOGRAPHIC SCREENING STUDY	17
Shire	OA Knee or Hip	Difram™	6
Pharmacia 249	OA Knee or Hip	Celecoxib	20
McNeil 00-103	OA Knee or Hip	Acetaminophen	16
Johnson and Johnson 42160443PAI2004	OA Knee or Hip	JNJ 42160443	8
Pfizer A4091030	OA Knee or Hip	Tanezumab	13




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

IROKO D1C3-08-05	OA KNEE OR HIP	DICLOFENAC NANOFORMULATION	25
Iroko MEL33-12-03	OA Knee or Hip	Meloxicam	7
Charleston CLCT-006	OA KNEE OR HIP	CCX168	9
Regeneron R475-PN-1523	OA Knee or Hip	Fasimumab	3
Regeneron R475-OA-1611	OA Knee or Hip	Fasimumab	5
Forest 03	OA of Knee or Hip	ML3000	32
Merck 066	OA or RA	Etoricoxib	99
Merck 003	OA or RA	L-001069957	26
Pfizer (Precision) A3191172	OA or RA	Celecoxib	65
Flexion FX006-2017-013	OA Shoulder or Hip	FX006	7
Endo EN3231-M030	OA with Chronic Pain	DEXTROMETHORPHAN	76
Nicox HCT3012-X-111	OA with HTN	Naproxcinod	5
Pharmacia/Pfizer	OA with HTN and DM	Celecoxib, Rofecoxib	16
Sanofi L8445	OA with Insomnia	Zolpidem	8
Merck 136	OA with Ulcers	MK-0966	79
Novartis CVAH631BUS06	Obese HTN	HCTZ	1
Sanofi-Synthelabo	Obese Patients with Dyslipidemia	SR141716	10
Merck 006	Obesity	L-000899055	15
Merck 015	Obesity	L-000899055	26
Merck 012	Obesity	MK-0364	24
Orexigen NB-CVOT	Obesity	Naltrexone/Bupropion SR	53
MERCK 053	OP FOR MEN	ODANACATIB	7
Lilly	OP Observational	Forteo®	20
Pfizer 1008-174	Open Label Disturbed Sleep from Neuropathic Pain	Pregabalin	1
Johnson and Johnson R331333-PAI-3024	Opioid Induced Constipation	Questionnaire	2
Johnson and Johnson R331333PAI3020	Opioid Induced Constipation	Tapentadol IR and Oxycodone IR	9
THERAVANCE TD-1211	Opioid Induced Constipation	TD-1211	0
Alza/Johnson and Johnson	Opioid Tolerant Patients	D-Trans® fentanyl	11
Roxanne	Osteoarthritis	Oxycodone	18
Noven	Osteoarthritis	Ketoprofen Patch	15
Pfizer TINE	Osteoarthritis	CP-544,439	16
Novartis 0117	Osteoarthritis	COX189	23
Novartis 2332	Osteoarthritis	COX189	35
Merck 061-00	Osteoarthritis	Etoricoxib vs Diclofenac	16
Merck 071	Osteoarthritis	Etoricoxib	35




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Labopharm MDT3-005	Osteoarthritis	Tramadol	11
Abbott M04-697	Osteoarthritis	Vicodin	18
Samumed SM04690-OA-10	Osteoarthritis	SM04690-OA-10	1
Purdue BUP3019	Osteoarthritis (Severe)	BTDS and OxyIR®	0
Acadia ACP-044-005	Osteoarthritis of the Knee	ACP-044	3
Techfields TF-X0002-31	Osteoarthritis of the Knee	X0002	2
Purdue 3011	Osteoarthritis Pain	Buprenorphine	4
Pfizer-Bones	Osteopenia	Atorvastatin	13
Pharmacia 200	Osteopenia	Celecoxib	3
Amgen 20040132	Osteopenia	AMG162	1
Primus FOS-01 PHASE 1	Osteopenia	Fosteum	20
Amgen 20060223 PHASE 1	Osteopenia	AMG 785	28
Amgen 20060221	Osteopenia Men	AMG 785	15
NPS/Allelix	Osteoporosis	PTH	20
Merck 005	Osteoporosis	L-845704	22
P & G and Aventis	Osteoporosis	Risedronate	17
Wyeth Ayerst 301	Osteoporosis	Bazedoxifene Acetate	3
Organon	Osteoporosis	Tibolone	5
Novartis 2301	Osteoporosis	Zoledronic Acid	4
Lilly B3D-MC-GHCD	Osteoporosis	Teriparatide and Raloxifene	12
Merck 211 (FACT)	Osteoporosis	Alendronate Risedronate	17
Merck 227	Osteoporosis	Alendronate	15
Roche MA17843	Osteoporosis	Ibandronate	21
Aventis HMR4003B/4034	Osteoporosis	Teriparatide	1
Lilly B3D-US-GHCQ	Osteoporosis	Arzoxifene	9
Amgen 20030216	Osteoporosis	AMG162	0
GlaxoSmithKline BON103593	Osteoporosis	Ibandronate	15
Merck 230	Osteoporosis	MK-217A	1
Amgen 20050141	Osteoporosis	Denosumab	9
Roche MA19547 (Balto III)	Osteoporosis	Boniva vs Actonel	22
Amgen 20050241 (Phase 1)	Osteoporosis	Denosumab	18
Deltanoid 2MD-3H-2B	Osteoporosis	DP001	12
GlaxoSmithKline CR9108963	Osteoporosis	SB-751689	9
Unigene/Tarsa UGL-OR0801	Osteoporosis	Calcitonin Nasal Spray	11
Merck 042.00	Osteoporosis	MK-0822	3




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Amgen 20080562	Osteoporosis	AMG 162 Denosumab	5
Merck 012-00	Osteoporosis	MK-5442	0
Amgen 20080389	Osteoporosis	AMG 167	27
AMGEN 2010218	Osteoporosis	PROLIA	20
Novartis CBPS804A2203 PHASE 1	Osteoporosis	BPS804	4
Amgen 20070337	Osteoporosis	AMG785	1
Amgen 20120187	Osteoporosis	Denosumab	1
LILLY B3D-EW-GHDW	Osteoporosis	Teriparatide and Risedronate	5
MERCK 076-01	Osteoporosis	MK-0822	2
Amgen 20101217	Osteoporosis	RISEDRONATE	4
Dr. Saag – EDGE study- NIH	Osteoporosis	Bisphosphonates	2
Pfenex PF708-301	Osteoporosis	PF708	11
Amgen 201707501	Osteoporosis	Romozosumab	3
National Bone Health Alliance: Dr. Silverman. Biochemical Markers of Bone Turnover from Drug Holiday from Bisphosphonates	Osteoporosis	Bisphosphonates	2
Amgen 20150120	Osteoporosis	Romozosumab	2
UC DAVIS LLP2A-001	Osteoporosis	LLP2A-Alendronate	42
Oscotec OSCOP2201	Osteoporosis	SKI-O-703	2
Sandoz CGP24112301	Osteoporosis	GP2411 (biosimilar)	1
Teva TVB009-IMB-30085	Osteoporosis	TVP-009P	2
Radius BA058-05-019	Osteoporosis – Men	Abaloparatide – SC	4
Roche BA20341	Osteoporosis / Renal Involvement	Ibandronate	4
GlaxoSmithKline BON05960	Osteoporosis for men	Boniva	13
Amgen 20080098	Osteoporosis for Men	DENOSUMAB	13
Wyeth Ayerst 300	Osteoporosis Prevention	TSE-424	16
Yamanouchi	Overactive Bladder	Vesicare®	12
Targacept TC-5214-23-CRD-003	Overactive Bladder	Dexmecamylamine	2
Actelion (Uncover)	PAH	Questionnaire	20
Actelion CHRC 015	PAH	Questionnaire	12
Wyeth 3200A3-1113-US	Pain	MOA-728	5
KING ALPHARMA CONVERT	PAIN	EMBEDA	6
Pozen PN200-301	Patients at Risk for Developing NSAID associated Ulcers	PN200	38
GlaxoSmithKline A1A20004	Peripheral Neuropathic Pain	GW493838	1




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

ABBOTT M10-883	Peripheral Spondyloarthritis	Humira	1
Purdue HMP3011	Persistent Pain	Hydromorphone Hydrochloride ER	0
Regeneron 0423	Polymyalgia Rheumatica	IL-1 Trap	0
Horizon HZNP-PRE-IIS02	Polymyalgia Rheumatica	Prednisone	3
AbbVie M20-370	Polymyalgia Rheumatica	ABBV-154	2
Trubuo (PHASE 1)	Polymyositis & Dermatomyositis	TRU-015	0
MedImmune MI-CP151 (Phase 1)	Polymyositis & Dermatomyositis	MEDI-545	2
Kezar KZR-616-003	Polymyositis & Dermatomyositis	KZR-616	2
Pfizer A6061001	Post Herpetic Neuralgia	S,S-Reboxetine	4
Pfizer A6061026	Post Herpetic Neuralgia	Reboxetine	2
King K862-06-2001	Post Herpetic Neuralgia	T-62	Sponsor Cancelled
Pfizer A4091005	Post Herpetic Neuralgia	RN624	3
Neurogesx C116	Post Herpetic Neuroalgia	NGXZ-4010	5
AstraZeneca 289	Prevention of Gastric Ulcers with daily NSAID use	NEXIUM	59
Sucampo SPI/8811SU-0621	Prevention of Ulcers	PI-8811	44
Neurocrine Biosciences	Primary Insomnia	NBI-34060	5
Alexion	Psoriasis	H5F1.1-mAb	8
Abgenix	Psoriasis	ABX-IL8	22
Genentech	Psoriasis	Efalizumab	7
Amgen 20030190	Psoriasis	Enbrel®	13
Novartis CAIN457B2102 PHASE 1	Psoriasis	AIN457	6
Schering Plough P04581 PHASE 1	Psoriasis	SCH 900875	4
Wyeth 3199K2-1105	Psoriasis	ILV-094	6
Novartis CAIN457A2204	Psoriasis	AIN457	2
Schering Plough P05382	Psoriasis	SCH 9000222	4
NOVARTIS CAIN457A2302	Psoriasis	SECUKINUMAB	2
Novartis CAIN457A2309	Psoriasis	SECUKINUMAB	4
Merck MK-3222-010	Psoriasis	SCH900222/MK-3222	7
Novartis CAIN457A2302	Psoriasis	SECUKINUMAB	2
Novartis CAIN457A2309	Psoriasis	SECUKINUMAB	4
Novartis CAIN457A2313	Psoriasis	SECUKINUMAB	1
Novartis CAIN457A2317	Psoriasis	USTEKINUMAB	0
COHERUS CHS-0214-04	Psoriasis	CHS0214	1
KADMON KD025-206	Psoriasis	PF-04965842	5




Altoona Center for Clinical Research
 175 Meadowbrook Lane, Duncansville PA 16635

Boehringer Ingelheim 1311.28	Psoriasis	RISANKIZUMAB VERSUS USTEKINUMAB	2
Kadmon KD025-206	Psoriasis	KD025	6
Janssen CNTO1959PSO1003	Psoriasis	CNTO 1959	1
Boehringer Ingelheim 1311.12	Psoriasis	BI 695501	5
Prothena Phase 1	Psoriasis	PRX003	2
CELEGENE CC-9006-CP-002 Phase 1	Psoriasis	CC-9006-CP-002	2
Arcutis ARQ-151-301	Psoriasis	ARQ-151	10
Serono	Psoriasis & Psoriatic Arthritis	Onercept	2
Amgen 20040210	Psoriasis (Post-Marketing Study)	Enbrel	10
Biogen (Atlas)	Psoriasis (Safety Study)	Amevive®	0
Amgen 20090176	Psoriasis Injector	Etanercept	15
Genentech ACD3101g	Psoriasis Questionnaire	Raptiva	24
Genentech ACD3101g	Psoriasis Registry	Raptiva	29
Lilly I7P-MC-DSAB	Psoriasis, Palmoplantar Pustulosis, Hidradenitis Suppura	LY3041658	7
Immunex	Psoriatic Arthritis	Enbrel	23
Pharmacia 202	Psoriatic Arthritis	Celecoxib	7
XOMA	Psoriatic Arthritis	Efalizumab	17
Abbott M02-570	Psoriatic Arthritis	Humira®	12
Centocor C0524T08	Psoriatic Arthritis	Golimumab	13
Bristol Myers IM101-158	Psoriatic Arthritis	Abatacept	12
CENTOCOR CNTO1275PSA3001	Psoriatic Arthritis	USTEKINUMAB	9
UCB SCHWARZ PSA001	Psoriatic Arthritis	CERTOLIZUMAB PEGOL	3
ROCHE PP22713/A	Psoriatic Arthritis	RO5310074	2
Centocor CNTO1275PSA3002	Psoriatic Arthritis	Ustekinumab	8
Novartis CAIN457A2306	Psoriatic Arthritis	SECUKINUMAB	6
Amgen 20101227	Psoriatic Arthritis	AMG827	9
Celgene CC-10004-PSA-005	Psoriatic Arthritis	Apremilast	6
Bristol Myers Squibb IM133-004-006	Psoriatic Arthritis	BMS-945429	0
Amgen 20110107	Psoriatic Arthritis	Enbrel	14
Celgene CC-10004-PSA-002	Psoriatic Arthritis	Apremilast	12
Novartis CAIN457F2312	Psoriatic Arthritis	SECUKINUMAB	8
LILLY I1F-MC-RHAP	Psoriatic Arthritis	LY2439821	1
Celgene CC-10004-PSA-006	Psoriatic Arthritis	Apremilast	3
Pfizer A3921091	Psoriatic Arthritis	Tofacitinib	1




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Novartis CAIN457F2318	Psoriatic Arthritis	Secukinumab	2
Amgen 20090406	Psoriatic Arthritis	Brodalumab	1
NOVARTIS CAIN457F2336	Psoriatic Arthritis	SECUKINUMAB	2
PFIZER A3921125	Psoriatic Arthritis	Tofacitinib	5
JANSSEN CNTO148PSA3001	Psoriatic Arthritis	Golimumab	2
LILLY I1F-MC-RHBE	Psoriatic Arthritis	LY2439821	5
Novartis CAIN457F2342	Psoriatic Arthritis	Secukinumab	1
AbbVie 1311.5	Psoriatic Arthritis	BI655066/ABBV-066/Risankizumab	5
Amgen 20130207	Psoriatic Arthritis	Etanercept	20
UCB PA0008	Psoriatic Arthritis	Bimekizumab	2
Novartis CAIN457FUS01	Psoriatic Arthritis	Secukinumab	5
NOVARTIS CAIN457F2366	Psoriatic Arthritis	SECUKINUMAB	3
AbbVie M15-554	Psoriatic Arthritis	UPADACITINIB (ABT-494)	20
AbbVie M14-496	Psoriatic Arthritis	ADALIMUMAB	5
AbbVie M15-572	Psoriatic Arthritis	UPADACITINIB	4
BMS IM011084	Psoriatic Arthritis	BMS-986165	3
AbbVie M15-998	Psoriatic Arthritis	RISANKIZUMAB	5
Gilead GS-US-431-4566	Psoriatic Arthritis	FILGOTINIB	1
Gilead GS-US-431-4567	Psoriatic Arthritis	FILGOTINIB	6
UCB PA0010	Psoriatic Arthritis	BIMEKIZUMAB	14
UCB PA0011	Psoriatic Arthritis	BIMEKIZUMAB	8
Novartis CAIN457P12302	Psoriatic Arthritis	SECUKINUMAB	11
Celgene CC-10004-PSA-013	Psoriatic Arthritis	CC-10004	6
Nimbus 4858-202	Psoriatic Arthritis	NDI034858	8
Bristol Myers Squibb IM011055	Psoriatic Arthritis	DEUCRAVACITINIB	9
Moonlake	Psoriatic Arthritis	M1095-PSA-201	1
Acelyrin 22104	Psoriatic Arthritis	Izokibep	4
Aclaris ATI-450-PsA-201	Psoriatic Arthritis	Zunsemetinib	4
Johnson & Johnson R331333-PAI-3002	Pts. Waiting for Joint Replacement	CG5503	4
Clintrials	Questionnaire for Venous Ulcer	None	10
Immunex Radius I	RA Questionnaire Study	None	53
Amgen 200990176	RA and Psoriasis	Enbrel Autoinjector	16
Pharmacia	RA in Juveniles and Adults	Celecoxib	40
Baxalta 911502	RA Injector	M923	12
Roche NP 22775	RA on BCP	Tocilizumab	19 Healthy




Altoona Center for Clinical Research
 175 Meadowbrook Lane, Duncansville PA 16635

			2 RA
AMGEN 20110107	RA or PSA	Enbrel Autoinjector	16
AstraZeneca D4300C00033	RA with ABPM	FOSTAMATINIB DISODIUM	1
Ortho Biotech	RA with Anemia	Procrit®	0
Amgen 20101324 PHASE 1	RA with Low Bone Mineral Density	Denosumab	7
PFIZER A7331010	Raynaud's	Phosphodiesterase 5 Inhibitor (PF-00489791)	5
Covis VAS-014-001	Raynaud's	Nitroglycerine, Vascana	17
Primus PVR-02	Raynaud's	Diosmiplex (Vasculera)	22
Ostuka 21-01-335	Raynaud's in Juveniles	Pletal (Cilostazol)	1
Otsuka	Raynaud's Phenomenon	OPC-28326	9
Takeda 01-01-TL-370-001	Regurgitation	TAK-370	4
Tap PACE-M02-420	Regurgitation	Lansoprazole verses Esomeprazole	1
Astellas 3606-CL-3010	Renal Impairment	Regadenoson	32
Amgen 20040245 PHASE 1	Renal Insufficiency	AMG162	1
Aventis Treat	Respiratory Tract Infections	Ketek®	12
GlaxoSmithKline	Restless Legs Syndrome	Ropinirole	1 (Sponsor Closed Study)
GSK – Xenoport RXP114025	Restless Legs Syndrome	GSK1838262	7
Bristol Myers Squibb 029	Rheumatoid Arthritis	BMS-188667	1
Pfizer A6261002 PHASE 1	Rheumatoid Arthritis	PD 0360324	9
Immunex	Rheumatoid Arthritis	Enbrel	49
Searle 076	Rheumatoid Arthritis	Valdecoxib	8
IDEC	Rheumatoid Arthritis	Clenoliximab	16
Alexion E99	Rheumatoid Arthritis	h5G1.1-mAb	6
Novartis (A2312)	Rheumatoid Arthritis	COX189	24
Knoll (S.O.N.O.R.A)	Rheumatoid Arthritis	Observational for RA	14
Abgenix	Rheumatoid Arthritis	ABX-IL8	19
Knoll	Rheumatoid Arthritis	Anti-TNF	26
Novartis 114	Rheumatoid Arthritis	Celecoxib	30
Vertex	Rheumatoid Arthritis	VX-745	6
Serono	Rheumatoid Arthritis	IFN-beta-1a	5
Serono 22766	Rheumatoid Arthritis	Onercept r-hTBP-1	7
Bristol Myers Squibb 101	Rheumatoid Arthritis	BMS-188667	2
Novartis 0110	Rheumatoid Arthritis	COX189	25
AstraZeneca	Rheumatoid Arthritis	ZD2315	8




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Amgen 143	Rheumatoid Arthritis	Kineret	16
Bristol Myers Squibb 100	Rheumatoid Arthritis	BMS-188667	7
Medimmune	Rheumatoid Arthritis	MEDI-522	5
Immunex 52.0003	Rheumatoid Arthritis	IL-1R _{II}	9
Regeneron Pharmaceuticals	Rheumatoid Arthritis	IL-1Trap	6
Medimmune CP083	Rheumatoid Arthritis	MEDI-522	2
Angiotech	Rheumatoid Arthritis	Paxeed™	8
Immunex 36	Rheumatoid Arthritis	Enbrel	15
Alexion C01-004	Rheumatoid Arthritis	h5G1.1-mAb	12
Amgen 238	Rheumatoid Arthritis	AMG 719	4
Amgen 198	Rheumatoid Arthritis	PEG sTNF-RI	2
Immunex 052.0005	Rheumatoid Arthritis	IL-1RI	5
Xoma	Rheumatoid Arthritis	Efalizumab	18
Regeneron IL1T-RA-0111	Rheumatoid Arthritis	IL1 Trap	2
Scios	Rheumatoid Arthritis	SCIO-469	13
GenMab 004	Rheumatoid Arthritis	HuMax-CD4	2
GenMab 002	Rheumatoid Arthritis	HuMax-CD4	8
Boehringer Ingelheim	Rheumatoid Arthritis	Meloxicam	26
ISIS	Rheumatoid Arthritis	TNF-alpha Antisense Oligonucleotide	15
Amgen 20020101	Rheumatoid Arthritis	Anakinra	10
Wyeth 3066A3-125-US	Rheumatoid Arthritis	CC1-779	4
Immunex Radius 2	Rheumatoid Arthritis	Enbrel	8
Bristol Myers Squibb 102	Rheumatoid Arthritis	BMS-188667	5
Abbott M02-498	Rheumatoid Arthritis	D2E7	17
Regeneron IL1T-RA-0102	Rheumatoid Arthritis	IL-1 Trap	9
Pharmacia 014	Rheumatoid Arthritis	CDP-870	4
Genentech	Rheumatoid Arthritis	MabThera®	3
Genmab	Rheumatoid Arthritis	Humax IL15	5
Phytomedics	Rheumatoid Arthritis	Tripterygium wilfordii Hook F	12
Novartis 2335	Rheumatoid Arthritis	COX 189	10
Aventis HMR3480A/2003	Rheumatoid Arthritis	HMR3480	18
IDEC	Rheumatoid Arthritis	Rituximab	3
Pfizer A3471018	Rheumatoid Arthritis	Bextra®	23
Merck 072	Rheumatoid Arthritis	Etoricoxib	20
Neurogen PHASE 1	Rheumatoid Arthritis	NGD 2000-1 Dibesylate	12




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Pharmacia 011	Rheumatoid Arthritis	CDP-870	4
GlaxoSmithKline CXA20006	Rheumatoid Arthritis	GW406381X	19
Bristol Myers Squibb 031	Rheumatoid Arthritis	BMS-188667	10
Fresenius Hemocare	Rheumatoid Arthritis	PROSORBA®	1
Abbott M03-600	Rheumatoid Arthritis	Adalimumab	32
Elan	Rheumatoid Arthritis	Antegren™ (Natalizumab 300 mg)	11
Wyeth 3066A3-206-WW	Rheumatoid Arthritis	CCI-779	8
Wyeth 3140A1-103-US	Rheumatoid Arthritis	TMI-005	4
Abbott (HERO) M04-684	Rheumatoid Arthritis	Humira®	22
Amgen 20030236	Rheumatoid Arthritis	Etanercept	11
NIH	Rheumatoid Arthritis	danJ peptide (dnaJp1)	8
Roche RB17861	Rheumatoid Arthritis	Observational	23
University of Alabama at Birmingham	Rheumatoid Arthritis	Etanercept	37
University of Massachusetts	Rheumatoid Arthritis	Marine and Botanical Oils	11
Wyeth 3140A1-200-WW	Rheumatoid Arthritis	TMI-005	4
Genentech ACT2847g	Rheumatoid Arthritis	rhuMAb 2H7	4
Scios B0007	Rheumatoid Arthritis	SCIO-469	15
Takeda 01-03-TI-715-005	Rheumatoid Arthritis	TAK-715	3
Trubuo (Phase 1)	Rheumatoid Arthritis	TRU-015	9
Amgen 20040201	Rheumatoid Arthritis	Enbrel	5
Fresenius Hemocare	Rheumatoid Arthritis	Prosorba	4
Pfizer A3921019	Rheumatoid Arthritis	CP-690,550	1
Regeneron IL1T-RA-0408	Rheumatoid Arthritis	IL-1 Trap	8
Roche WA17823	Rheumatoid Arthritis	MRA	9
Celltech CDP870-027	Rheumatoid Arthritis	CDP-870	0
Merrimack MM-093-01-200	Rheumatoid Arthritis	MM-093	5
Genmab HX-CD20-403	Rheumatoid Arthritis	HuMax CD20	6
GlaxoSmithKline CXA30009	Rheumatoid Arthritis	GW406381	15
Incyte (Phase I)	Rheumatoid Arthritis	INCB003284	11
Amgen 20040275	Rheumatoid Arthritis	Enbrel	2
Genentech BRT3321g	Rheumatoid Arthritis	PRO97796 (BR3-Fc)	4
Roche WA17824	Rheumatoid Arthritis	MRA	9
Roche WA18062	Rheumatoid Arthritis	MRA	3




Altoona Center for Clinical Research
 175 Meadowbrook Lane, Duncansville PA 16635

Wyeth 3142A1-202	Rheumatoid Arthritis	ERB-041	2
CombinatorX	Rheumatoid Arthritis	CRX-119N	1
Wyeth TD-04-02	Rheumatoid Arthritis	ERB-041	13
Targeted Genetics PHASE 1	Rheumatoid Arthritis	TNFR-Fc Fusion Gene	11
Bristol Myers 023	Rheumatoid Arthritis	Abatacept	2
Rigel C-935788-004 PHASE 1	Rheumatoid Arthritis	R935788	8
Centocor C0524T06	Rheumatoid Arthritis	Golimumab	5
Centocor C0524T05	Rheumatoid Arthritis	Golimumab	8
Centocor C0524T11	Rheumatoid Arthritis	Golimumab	8
Roche WP18663	Rheumatoid Arthritis	MRA	16
Genentech U3384g	Rheumatoid Arthritis	Rituximab	0
Genentech U3374g	Rheumatoid Arthritis	Rituximab	5
Genentech U3373g	Rheumatoid Arthritis	Rituximab	6
Merck 086	Rheumatoid Arthritis	Etoricoxib	7
Regeneron 0404	Rheumatoid Arthritis	IL1 Trap	0
Abbott M05-770	Rheumatoid Arthritis	Humira	7
Amgen 20050168	Rheumatoid Arthritis	AMG 108	5
PDL BioPharma	Rheumatoid Arthritis	Fontolizumab	9
Biogen-Idec 102-RA-201	Rheumatoid Arthritis	Rituxin	2
University of PA	Rheumatoid Arthritis	Questionnaire for MTX	150
Centocor C0524T12	Rheumatoid Arthritis	Golimumab	7
Rigel C-935788-006	Rheumatoid Arthritis	R935788	11
Alza / J & J C-2006-009-01	Rheumatoid Arthritis	RJW – 445380	5
Proctor and Gamble 2005012	Rheumatoid Arthritis	PG-760564	2
Abbott M06-810	Rheumatoid Arthritis	Humira	16
Genentech WA20494/ACT3985	Rheumatoid Arthritis	Ocrelizumab	1
Genentech U3839g (Sunstone)	Rheumatoid Arthritis	Rituxin	0
Genentech WA20497/ACT3984g	Rheumatoid Arthritis	Ocrelizumab	2
Pfizer A4001056	Rheumatoid Arthritis	Maraviroc	17
Merrimack MM-093-01-201	Rheumatoid Arthritis	MM-093	8
Pfizer A6341006 PHASE 1	Rheumatoid Arthritis	CE-224,535	13
Pfizer A3921035	Rheumatoid Arthritis	CP-690,550	4
Biogen 104-RA-203	Rheumatoid Arthritis	BG9924	0
INCYTE INCB 18424-231	Rheumatoid Arthritis	INCB018424 Ruxolitinib	Sponsor Closed Study
Roche WA19923	Rheumatoid Arthritis	Tocilizumab	3
Adolor 33CL232	Rheumatoid Arthritis	ADL5859	10




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Serono 27905	Rheumatoid Arthritis	Atacicept	2
Regeneron 6R88-RA-0703 PHASE 1	Rheumatoid Arthritis	REGN88 (IL6R-mAb)	3
Medarex MDX1342-01 PHASE 1	Rheumatoid Arthritis	MDX-1342	1
Combinatorx CRx-102-007	Rheumatoid Arthritis	CRX-102	0
Bristol Myers IM101-167	Rheumatoid Arthritis	Abatacept	12
Bristol Myers IM101-173	Rheumatoid Arthritis	Abatacept	8
Abbott M10-261	Rheumatoid Arthritis	Humira	16
Centocor C0524T14 PHASE 1	Rheumatoid Arthritis	Golimumab	6
Pfizer A6631005	Rheumatoid Arthritis	PH-797804	5
Incyte 28050-103 PHASE 1	Rheumatoid Arthritis	INCB028050 - Baricitinib	19
Pfizer A6261002	Rheumatoid Arthritis	0360324	10
Regeneron 6R88-RA-0802	Rheumatoid Arthritis	REGN88	9
Genentech U3924g (SUNDIAL)	Rheumatoid Arthritis	Rituximab	2
Centocor Restart C0168Z05	Rheumatoid Arthritis	Golimumab	8
Pfizer A3921045	Rheumatoid Arthritis	CP-690,550	13
Biogen TWEEK 211RA101	Rheumatoid Arthritis	BIIB023	9
Genentech CDT4478g	Rheumatoid Arthritis	MTRX1011A	3
Amgen 20070441	Rheumatoid Arthritis	Observational Study	3
Centocor C1377T04	Rheumatoid Arthritis	CNTO 136	2
NIH -ACE02	Rheumatoid Arthritis	LOVASTATIN	1
Incyte INCB 28050-103	Rheumatoid Arthritis	INCB 28050	28
Nuon A3003RA	Rheumatoid Arthritis	Tranilast	7
Roche ML22533	Rheumatoid Arthritis	Tocilizumab	6
Incyte INCB 28050-201	Rheumatoid Arthritis	INCB 2805	3
ROCHE WA19926	Rheumatoid Arthritis	ACTEMRA	7
PFIZER A3921069	Rheumatoid Arthritis	CP-690,550	7
ANTARES	Rheumatoid Arthritis	MTX AUTOINJECTOR	36
UCB/SWARTZ RA0017	Rheumatoid Arthritis	Certolizumab Pegol	22
LexiconLX3305.201	Rheumatoid Arthritis	LX3305	3
Pfizer A9391005	Rheumatoid Arthritis	PF-04171327	4
Pfizer B0151002	Rheumatoid Arthritis	PF-04236921	5
UCB 87077	Rheumatoid Arthritis	Certolizumab Pegol	13
Genentech ALT4623g	Rheumatoid Arthritis	MLTA3698A	8
UCB RA0010	Rheumatoid Arthritis	CDP6038	5
Wyeth 3199K1-2001-WW	Rheumatoid Arthritis	ILV-094	14




Altoona Center for Clinical Research
 175 Meadowbrook Lane, Duncansville PA 16635

Bristol Myers Squibb IM101-235	Rheumatoid Arthritis	Abatacept	7
Amgen 20090061	Rheumatoid Arthritis	AMG 827	3
NIH – ACE – ARA05	Rheumatoid Arthritis	Switch to Anti-TNF	1
REGENERON 000-RA-1008	Rheumatoid Arthritis	ACTEMRA	3
ROCHE WA19924	Rheumatoid Arthritis	ACTEMRA	4
ANTARES	Rheumatoid Arthritis	MTX AUTOINJECTOR	36
VERTEX	Rheumatoid Arthritis	VX-509	6
BIOGEN IDEC 99RA002 Batter Up	Rheumatoid Arthritis	Blood Draw	3
SANOFI AVENTIS ACT11575	Rheumatoid Arthritis	SAR153191	0
UCB RA0056	Rheumatoid Arthritis	CIMZIA	4
ABBOTT M12-073	Rheumatoid Arthritis	HUMIRA	7
ASTRAZENECA D4300C00002	Rheumatoid Arthritis	FOSTAMATINIB DISODIUM	2
AstraZeneca D4300C00004	Rheumatoid Arthritis	FOSTAMATINIB DISODIUM	5
AstraZeneca D4300C00002	Rheumatoid Arthritis	FOSTAMATINIB DISODIUM	2
Roche NA25220	Rheumatoid Arthritis	Tocilizumab	7
ASTELLAS 2408-CL-0103	Rheumatoid Arthritis	ORENCIA	8
Sanofi Aventis PKM12058 PHASE 1	Rheumatoid Arthritis	SAR153191	11
Lilly 14V-MC-JADA	Rheumatoid Arthritis	LY3009104	3
Celgene CC-10004-RA-002	Rheumatoid Arthritis	Apremilast	10
UCB (SWITCH) CERT-001	Rheumatoid Arthritis	Cimzia	2
J & J 38518168ARA1001 PHASE 1	Rheumatoid Arthritis	NJ-38518168	7
J & J 39758979ARA1001 PHASE 1	Rheumatoid Arthritis	JNJ39758979	2
Roche Visara NA25256	Rheumatoid Arthritis	Tocilizumab	6
ROCHE MA25522	Rheumatoid Arthritis	TOCILIZUMAB	1
UCB RA0064	Rheumatoid Arthritis	Cimzia	26
PFIZER A3921129 - 1014	Rheumatoid Arthritis	CP-690,550	9
Chelsea CH-4051-RA202	Rheumatoid Arthritis	CH-4051	1
Celgene CCT-PDA001-RA-001	Rheumatoid Arthritis	PDA001	4
Plexxikon PLX115-02 PHASE 1	Rheumatoid Arthritis	PLX3397	8
Centocor GoSave CNTO148ART3002	Rheumatoid Arthritis	Golimumab	5
ZALICUS Z102-008	Rheumatoid Arthritis	Z102	5
PORTOLA (PHASE 1)	Rheumatoid Arthritis	PRT062607	15
Roche WA25204 Entracte	Rheumatoid Arthritis	Actemra	3
UCB RA0055	Rheumatoid Arthritis	Cimzia	11
UCB RA0077	Rheumatoid Arthritis	Cimzia	0
Pfizer A9391010	Rheumatoid Arthritis	PF-04171327	5




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Medac MC-MTX.15/HF	Rheumatoid Arthritis	MTX AUTOINJECTOR	28
Antares MTX-11-002	Rheumatoid Arthritis	MTX AUTOINJECTOR	25
Antares MTX-11-003	Rheumatoid Arthritis	MTX AUTOINJECTOR	31
AstraZeneca D4300C00003	Rheumatoid Arthritis	FOSTAMATINIB DISODIUM	1
Bristol Myers Squibb IM126-004	Rheumatoid Arthritis	BMS817399	8
Pfizer A3921152	Rheumatoid Arthritis	CP-690,550	13
Antares MTX-11-002	Rheumatoid Arthritis	MTX Injector	25
Antares MTX-11-003	Rheumatoid Arthritis	MTX Injector	31
Sanofi EFC11072 MOBILITY	Rheumatoid Arthritis	SAR153191	10
Genentech ML25641 Rate-RA	Rheumatoid Arthritis	Rituximab	3
Astellas 2409-CL-0201	Rheumatoid Arthritis	ASP2408	10
Medac MC-MTX.15/HF	Rheumatoid Arthritis	MTX Injector	28
Pfizer B3281001	Rheumatoid Arthritis	PF-05280586	5
Vertex VX11-509-102	Rheumatoid Arthritis	VX509	1
Incyte INCB39110-201	Rheumatoid Arthritis	INCB039110	5
Astellas 2409-CL-0104	Rheumatoid Arthritis	ASP2409	19
Vertex VX12-509-103	Rheumatoid Arthritis	VX-509	1
Astellas 015K-CL-RA22	Rheumatoid Arthritis	ASP015K	10
Astellas 015K-CL-RA21	Rheumatoid Arthritis	ASP015K	6
AstraZeneca D4300C00004	Rheumatoid Arthritis	FOSTAMATINIB DISODIUM	5
Molecular Research (Camcargo) MRC2011-001	Rheumatoid Arthritis	MRC375	24
Abbott M12-071	Rheumatoid Arthritis	HUMIRA	11
AbbVie M13-550	Rheumatoid Arthritis	ABT-494	4
Pfizer A3921133	Rheumatoid Arthritis	TOFACITNIB	20
AMPLIMMUNE AMP-110-01 PHASE 1	Rheumatoid Arthritis	RA-AMP-110	9
BMS 101-366	Rheumatoid Arthritis	ABATACEPT INJECTOR	28
Protalex PRTX-100-104 Phase 1	Rheumatoid Arthritis	PRTX-100	11
AbbVie M14-048	Rheumatoid Arthritis	ABT 122	7
Boehringer Ingelheim	Rheumatoid Arthritis	BI 695500 vs Rituximab	0
Merck 0663-107	Rheumatoid Arthritis	MK-0663	23
Morphotek	Rheumatoid Arthritis	MORAB-022	12
Amplimmune AMP-110-01	Rheumatoid Arthritis	AMP-110	13
BMS 101-366	Rheumatoid Arthritis	ABATACEPT INJECTOR	28
SANOFI EFC13752	Rheumatoid Arthritis	SARILUMAB	3
JANSSEN CNTO148ART3003	Rheumatoid Arthritis	REMICADE	0
SANOFI MSC12665	Rheumatoid Arthritis	SARILUMAB	3




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

GALAPAGOS GLP0634-CL-203	Rheumatoid Arthritis	GLPG0634	0
GALAPAGOS GLP0634-CL-204	Rheumatoid Arthritis	GLPG0634	0
AMGEN 20120125	Rheumatoid Arthritis	ETANERCEPT	1
Pfizer A3921237	Rheumatoid Arthritis	TOFACITINIB	8
COHERUS CHS-0214-02	Rheumatoid Arthritis	CHS 0214	8
Janssen CNTO148ARA3002	Rheumatoid Arthritis	CNTO136 SIRUKAMAB	20
Janssen CNTO148ARA3004	Rheumatoid Arthritis	CNTO136 SIRUKAMAB	5
PHARMACYCLICS PCYC-1301-RA PHASE 1	Rheumatoid Arthritis	PCI-45466	6
Genentech BrevactaWA29917	Rheumatoid Arthritis	Tocilizumab	8
SANOFI INT12684	Rheumatoid Arthritis	SARILUMAB	3
ABBVIE M13-537	Rheumatoid Arthritis	ABT-494	3
Pfizer A3921187	Rheumatoid Arthritis	TOFACITINIB	6
Pfizer B5371002	Rheumatoid Arthritis	OF-06438179	4
Genentech ML28776	Rheumatoid Arthritis	Tocilizumab	6
CRESCENDO 083-CL-01	Rheumatoid Arthritis	VECTRADA	39
ABBVIE M14-197	Rheumatoid Arthritis	ABT-122	2
CELGENE CC-292-RA-001	Rheumatoid Arthritis	CC-292	7
PFIZER B5381002	Rheumatoid Arthritis	PF-06410293	2
FUJIFILM FKB327-002	Rheumatoid Arthritis	FKB327	4
Sandoz GP13-302	Rheumatoid Arthritis	GP13-302	2
Acerta ACE-RA-001	Rheumatoid Arthritis	ACP-196	0
Amgen 20110247	Rheumatoid Arthritis	AMG 357	4
Novartis CCFZ533X2101 PHASE 1	Rheumatoid Arthritis	CFZ533	2
Gilead GS-US-407-1833	Rheumatoid Arthritis	GS-4059	9
Astellas 5094-CL-0102 PHASE 1	Rheumatoid Arthritis	ASP5094	4
BMS IM101-550	Rheumatoid Arthritis	Abatacept	4
Lilly 18K-MC-JPDA	Rheumatoid Arthritis	LY337641	10
Merck MS200527-0081	Rheumatoid Arthritis	M2951	1
AbbVie M13-549	Rheumatoid Arthritis	ABT-494	5
Gilead GS-US-379-1582	Rheumatoid Arthritis	GS-9876	12
GlaxoSmithKline 205180	Rheumatoid Arthritis	GSK3196165	5
MedImmune D5100C00002 PHASE 1	Rheumatoid Arthritis	MED14920	10
AbbVie M14-465	Rheumatoid Arthritis	ABT-494	2
GlaxoSmithKline 205180	Rheumatoid Arthritis	GSK3196165	4
ABBVIE M14-500	Rheumatoid Arthritis	ABT-494	3
Pfizer A3921192	Rheumatoid Arthritis	Tofacitinib	18




Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Amgen 20130108	Rheumatoid Arthritis	ABP-798	4
Bristol Myers Squibb IM101-567	Rheumatoid Arthritis	Abatacept	3
Gilead GS-US-417-0301	Rheumatoid Arthritis	Filgotinib	2
Gilead GS-US-417-0303	Rheumatoid Arthritis	Filgotinib	15
Amgen 20110186	Rheumatoid Arthritis	Etanercept	9
Janssen Aware CNTO148ART4001	Rheumatoid Arthritis	Simponi Aria vs Remicade	7
Nichi-Iko NI071F2	Rheumatoid Arthritis	NI-071 & Remicade	7
Roche BP39261 SECARA	Rheumatoid Arthritis	RO7123520	4
Set Point SPM-008	Rheumatoid Arthritis	Device/Vagal Stimulator	4
R-PHARM CL04041023	Rheumatoid Arthritis	Olokizumab	4
AbbVie M15-925	Rheumatoid Arthritis	ABT-494	3
Amgen 20150196	Rheumatoid Arthritis	AMG 570	7
Crescendo 088-CL-01	Rheumatoid Arthritis	Vectra DA Outcomes Study	2
Lilly 14V-MC-JAJA	Rheumatoid Arthritis	BARICITINIB	30
Crescendo 133-CL-01	Rheumatoid Arthritis	Vectra Blood Test	60
Amgen 20170149	Rheumatoid Arthritis	AMG 592	1
Sanofi OBS14924	Rheumatoid Arthritis	Sarilumab	26
Navidea NAV3-31	Rheumatoid Arthritis	Tilmanocept Uptake Value on Tc99m Tilmanocept Planar Imaging	15
Oscotec OSCO-P2201	Rheumatoid Arthritis	SKI-O-703	2
Vielabio VIB4920.P2.S3	Rheumatoid Arthritis	VIB4920	1
TARGET Trial	Rheumatoid Arthritis	TREATMENTS AGAINST RA & EFFECT ON PET/CT SCAN	9
ACLARIS	Rheumatoid Arthritis	ATI-450	6
PFIZER B5381012	Rheumatoid Arthritis	PF-06410293	1
Lilly J1A-MC-KDAD	Rheumatoid Arthritis	LY3462817	2
GlaxoSmithKline 201791	Rheumatoid Arthritis	GSK3196165	1
UCB RA0138	Rheumatoid Arthritis	Electrochemiluminescent Immuno-Assay	11
Dr. Reddy	Rheumatoid Arthritis	DRL_RI	4
Vorso VC2020-7	Rheumatoid Arthritis	Vorso Protect System - Nerve Stimulator	9
BMS IM014029	Rheumatoid Arthritis	Abatacept	1
Bristol Myers Squibb IM101-863	Rheumatoid Arthritis	Abatacept vs Adalimumab	2
Bristol Myers Squibb IM014029	Rheumatoid Arthritis	Branerutinib	1
Lilly J1A-MC-KDAD	Rheumatoid Arthritis	LY3472817	2
AbbVie M20-466	Rheumatoid Arthritis	ABBV-154	8
SynAct-CS006	Rheumatoid Arthritis	AP1189	8
Lilly J1A-MC-KDAF	Rheumatoid Arthritis	Peresolimab	1



Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Aclaris ATI-450-RA-202	Rheumatoid Arthritis	ATI-450	6
Janssen 80202135ARA2002	Rheumatoid Arthritis	Nipocalimab & Certolizumab	2
Genentech BRT3766g PHASE 1	Rheumatoid Arthritis (Phase 1)	PRO97769	3
Novartis CAIN457A2101 PHASE 1	Rheumatoid Arthritis (Phase 1)	AIN457	9
ARRAY ARRY-162-0603 PHASE 1	Rheumatoid Arthritis (Phase 1)	ARRY-438162	21
Incyte INCB 18424-136 PHASE 1	Rheumatoid Arthritis (Phase 1)	INCB018424 Ruxolitinib	14
Regeneron 6R88-RA-0801 PHASE 1	Rheumatoid Arthritis (Phase 1)	REGN88	6
Merck 026	Rheumatoid Arthritis GI	Cox II	38
Amgen 20090176	Rheumatoid Arthritis Injector	Etanercept	15
Regeneron R1033-SRC-1239	Sarcopenia	REGN1033	1
Regeneron R475-PN-0908	Sciatica	REGN475	8
BIOGEN 103NS201	Sciatica	BG00010	8
Actelion MDP-001	Scleroderma	Questionnaire	8
MedImmune MI-CP200	Scleroderma	MEDI 551	1
Actelion DUAL1/AC055C301	Sclerosis – Digital Ulcers	Macitentan	1
Hisamitsu HKT400US03	Shoulder Pain	Ketaprofen Patch	9
Parion 552-207S	Sjogren's Syndrome	552-02	16
F. Hoffmann La Roche BP30037	Sjogren's Syndrome	RO5459072	1
BMS IM128-035	Sjogren's Syndrome	BMS -986142	1
BMS IM101-603	Sjogren's Syndrome	Abatacept	2
Lilly 16M-MC-SSAD	Sjogren's Syndrome	LY3090106	5
Gilead GS-US-445-4189	Sjogren's Syndrome	Filgotinib	2
Primus PSS-01	Sjogren's Syndrome	Survey	8
Servier CL2-95011-001	Sjogren's Syndrome	S95011	1
Janssen 80202135JS2001	Sjogren's Syndrome	Nipocalimab	3
Novartis CVAY736A2301	Sjogren's Syndrome	Ianalumab	3
Novartis CCFZ533X2203	Sjogrens Syndrome	CFZ533	2
Vielabio VIB4920-PS-S2	Sjogren's Syndrome	VIB4920	2
Philip Morris	Smokers	No Drug	113
Phillip Morris 7435-112	Smokers	Nicotine	2
Achieve Life Sciences ACH-CYT-04 (ORCA-3 Trial)	Smokers	Cytisinicline	35
NARAC	Trio Families with RA	Blood Collection	10
Pharmacia 198	Ulcerative Colitis	Celecoxib	6
Otsuka 197-02-220	Ulcerative Colitis	OPC-6535 & Asacol®	0



Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville PA 16635

Cosmo CB-01-02/01	Ulcerative Colitis	ASACOL	1
VERVE	Vaccine	Shingles	19
Pfizer C4601003	Vaccine	Lyme Disease	304
COVER-CoAd	Vaccine	Covid19	25
EISAI APD356-G000-401	Weight Loss	BELVIQ	6
TorreyPines NGX267XSS2001 PHASE 1	Xerostomia Associated with Sjögren's Syndrome	NGX267	12